Company Quick10K Filing
AptarGroup
Price118.51 EPS4
Shares67 P/E34
MCap7,905 P/FCF21
Net Debt872 EBIT342
TEV8,777 TEV/EBIT26
TTM 2019-09-30, in MM, except price, ratios
10-K 2020-12-31 Filed 2021-02-19
10-Q 2020-09-30 Filed 2020-10-30
10-Q 2020-06-30 Filed 2020-07-31
10-Q 2020-03-31 Filed 2020-05-01
10-K 2019-12-31 Filed 2020-02-24
10-Q 2019-09-30 Filed 2019-11-01
10-Q 2019-06-30 Filed 2019-08-01
10-Q 2019-03-31 Filed 2019-05-01
10-K 2018-12-31 Filed 2019-02-21
10-Q 2018-09-30 Filed 2018-11-05
10-Q 2018-06-30 Filed 2018-08-01
10-Q 2018-03-31 Filed 2018-05-03
10-K 2017-12-31 Filed 2018-02-26
10-Q 2017-09-30 Filed 2017-11-01
10-Q 2017-06-30 Filed 2017-08-02
10-Q 2017-03-31 Filed 2017-05-01
10-K 2016-12-31 Filed 2017-02-27
10-Q 2016-09-30 Filed 2016-11-04
10-Q 2016-06-30 Filed 2016-08-01
10-Q 2016-03-31 Filed 2016-05-03
10-K 2015-12-31 Filed 2016-02-25
10-Q 2015-09-30 Filed 2015-11-05
10-Q 2015-06-30 Filed 2015-07-31
10-Q 2015-03-31 Filed 2015-05-04
10-K 2014-12-31 Filed 2015-02-27
10-Q 2014-09-30 Filed 2014-11-06
10-Q 2014-06-30 Filed 2014-08-04
10-Q 2014-03-31 Filed 2014-05-05
10-K 2013-12-31 Filed 2014-02-28
10-Q 2013-09-30 Filed 2013-11-04
10-Q 2013-06-30 Filed 2013-08-05
10-Q 2013-03-31 Filed 2013-05-06
10-K 2012-12-31 Filed 2013-02-28
10-Q 2012-09-30 Filed 2012-11-02
10-Q 2012-06-30 Filed 2012-08-06
10-Q 2012-03-31 Filed 2012-05-08
10-K 2011-12-31 Filed 2012-02-24
10-Q 2011-09-30 Filed 2011-11-02
10-Q 2011-06-30 Filed 2011-08-03
10-Q 2011-03-31 Filed 2011-05-09
10-K 2010-12-31 Filed 2011-02-25
10-Q 2010-09-30 Filed 2010-11-03
10-Q 2010-06-30 Filed 2010-08-04
10-Q 2010-03-31 Filed 2010-05-04
10-K 2009-12-31 Filed 2010-02-26
8-K 2021-02-18 Earnings, Exhibits
8-K 2020-10-29
8-K 2020-09-09
8-K 2020-07-30
8-K 2020-05-06
8-K 2020-04-30
8-K 2020-02-20
8-K 2019-10-31
8-K 2019-07-31
8-K 2019-05-01
8-K 2019-04-30
8-K 2019-02-20
8-K 2018-11-01
8-K 2018-07-26
8-K 2018-06-12
8-K 2018-05-02
8-K 2018-04-26
8-K 2018-02-12
8-K 2018-02-08
8-K 2018-01-18

ATR 10K Annual Report

Part I
Item 1. Business
Item 1A. Risk Factors
Item 1B. Unresolved Staff Comments
Item 2. Properties
Item 3. Legal Proceedings
Item 4. Mine Safety Disclosures
Part II
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Item 6. Selected Financial Data
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Item 8. Financial Statements and Supplementary Data
Note 1 Summary of Significant Accounting Policies
Note 2 Revenue
Note 3 Inventories
Note 5 Accounts Payable, Accrued and Other Liabilities
Note 6 Income Taxes
Note 7 Debt
Note 8 Lease Commitments
Note 9 Retirement and Deferred Compensation Plans
Note 10 Accumulated Other Comprehensive Income/(Loss)
Note 11 Derivative Instruments and Hedging Activities
Note 12 Fair Value
Note 13 Commitments and Contingencies
Note 14 Stock Repurchase Program
Note 15 Capital Stock
Note 16 Stock - Based Compensation
Note 17 Earnings per Share
Note 18 Segment Information
Note 19 Acquisitions
Note 20 Investment in Equity Securities
Note 21 Restructuring Initiatives
Note 22 Quarterly Data (Unaudited)
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Item 9A. Controls and Procedures
Item 9B. Other Information
Part III
Item 10. Directors, Executive Officers and Corporate Governance
Item 11. Executive Compensation
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 13. Certain Relationships and Related Transactions, and Director Independence
Item 14. Principal Accountant Fees and Services
Part IV
Item 15. Exhibits and Financial Statement Schedules
Item 16. Form 10 - K Summary
EX-4.17 atr-20201231x10kexx417.htm
EX-10.16 atr-20201231x10kexx1016.htm
EX-10.37 atr-20201231x10kexx1037.htm
EX-10.57 atr-20201231x10kexx1057.htm
EX-21 atr-20201231x10kexx21.htm
EX-23 atr-20201231x10kexx23.htm
EX-31.1 atr-20201231x10kexx311.htm
EX-31.2 atr-20201231x10kexx312.htm
EX-32.1 atr-20201231x10kexx321.htm
EX-32.2 atr-20201231x10kexx322.htm

AptarGroup Earnings 2020-12-31

Balance SheetIncome StatementCash Flow
3.62.92.21.40.70.02012201420172020
Assets, Equity
0.80.60.50.30.20.02012201420172020
Rev, G Profit, Net Income
0.70.40.2-0.1-0.3-0.62012201420172020
Ops, Inv, Fin

atr-20201231
2020FY0000896622falseus-gaap:AccountingStandardsUpdate201409Memberus-gaap:AccountingStandardsUpdate201613Memberus-gaap:AccountsPayableAndAccruedLiabilitiesCurrentus-gaap:AccountsPayableAndAccruedLiabilitiesCurrentus-gaap:OperatingLeaseLiabilityNoncurrentus-gaap:OperatingLeaseLiabilityNoncurrent00008966222020-01-012020-12-31iso4217:USD00008966222020-06-30xbrli:shares00008966222021-02-1500008966222019-01-012019-12-3100008966222018-01-012018-12-31iso4217:USDxbrli:shares00008966222020-12-3100008966222019-12-310000896622us-gaap:RetainedEarningsMember2017-12-310000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310000896622us-gaap:CommonStockMember2017-12-310000896622us-gaap:TreasuryStockMember2017-12-310000896622us-gaap:AdditionalPaidInCapitalMember2017-12-310000896622us-gaap:NoncontrollingInterestMember2017-12-3100008966222017-12-310000896622us-gaap:RetainedEarningsMember2018-01-012018-12-310000896622us-gaap:NoncontrollingInterestMember2018-01-012018-12-310000896622us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2017-12-310000896622srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2017-12-310000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310000896622us-gaap:CommonStockMember2018-01-012018-12-310000896622us-gaap:TreasuryStockMember2018-01-012018-12-310000896622us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-310000896622us-gaap:RetainedEarningsMember2018-12-310000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000896622us-gaap:CommonStockMember2018-12-310000896622us-gaap:TreasuryStockMember2018-12-310000896622us-gaap:AdditionalPaidInCapitalMember2018-12-310000896622us-gaap:NoncontrollingInterestMember2018-12-3100008966222018-12-310000896622us-gaap:RetainedEarningsMember2019-01-012019-12-310000896622us-gaap:NoncontrollingInterestMember2019-01-012019-12-310000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310000896622us-gaap:CommonStockMember2019-01-012019-12-310000896622us-gaap:TreasuryStockMember2019-01-012019-12-310000896622us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310000896622us-gaap:RetainedEarningsMember2019-12-310000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000896622us-gaap:CommonStockMember2019-12-310000896622us-gaap:TreasuryStockMember2019-12-310000896622us-gaap:AdditionalPaidInCapitalMember2019-12-310000896622us-gaap:NoncontrollingInterestMember2019-12-310000896622us-gaap:RetainedEarningsMember2020-01-012020-12-310000896622us-gaap:NoncontrollingInterestMember2020-01-012020-12-310000896622us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000896622srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000896622us-gaap:CommonStockMember2020-01-012020-12-310000896622us-gaap:TreasuryStockMember2020-01-012020-12-310000896622us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310000896622us-gaap:RetainedEarningsMember2020-12-310000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000896622us-gaap:CommonStockMember2020-12-310000896622us-gaap:TreasuryStockMember2020-12-310000896622us-gaap:AdditionalPaidInCapitalMember2020-12-310000896622us-gaap:NoncontrollingInterestMember2020-12-310000896622country:AR2020-04-012020-06-30xbrli:pure0000896622us-gaap:SalesRevenueNetMembersrt:MaximumMemberus-gaap:GeographicConcentrationRiskMembercountry:AR2020-01-012020-12-310000896622us-gaap:PreferredStockMember2018-05-310000896622us-gaap:PreferredStockMember2018-01-012018-12-310000896622us-gaap:PreferredStockMember2019-01-012019-01-310000896622us-gaap:PreferredStockMemberatr:LoopAndPurecycleMember2019-08-012019-08-31atr:investment0000896622us-gaap:PreferredStockMemberatr:LoopAndPurecycleMember2019-08-310000896622us-gaap:PreferredStockMemberatr:LoopAndPurecycleMember2020-01-012020-12-310000896622atr:PurecycleMemberus-gaap:PreferredStockMember2020-01-012020-12-310000896622atr:PurecycleMemberus-gaap:PreferredStockMember2020-11-012020-11-300000896622atr:KaliCareMember2020-10-012020-12-310000896622us-gaap:BuildingAndBuildingImprovementsMembersrt:MinimumMember2020-01-012020-12-310000896622srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2020-01-012020-12-310000896622us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2020-01-012020-12-310000896622us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2020-01-012020-12-310000896622srt:MinimumMemberus-gaap:FiniteLivedIntangibleAssetsMember2020-01-012020-12-310000896622srt:MaximumMemberus-gaap:FiniteLivedIntangibleAssetsMember2020-01-012020-12-310000896622us-gaap:AccountingStandardsUpdate201602Memberatr:RestatementOfBeginningBalanceMember2020-01-012020-12-310000896622us-gaap:AccountingStandardsUpdate201602Membersrt:RestatementAdjustmentMember2019-01-0100008966222019-01-010000896622us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Memberus-gaap:AccountingStandardsUpdate201409Member2018-01-010000896622us-gaap:RetainedEarningsMember2018-10-012018-12-310000896622srt:RestatementAdjustmentMemberus-gaap:AccountingStandardsUpdate201613Member2020-01-010000896622srt:EuropeMemberatr:PharmaMember2020-01-012020-12-310000896622srt:NorthAmericaMemberatr:PharmaMember2020-01-012020-12-310000896622srt:LatinAmericaMemberatr:PharmaMember2020-01-012020-12-310000896622srt:AsiaMemberatr:PharmaMember2020-01-012020-12-310000896622atr:PharmaMember2020-01-012020-12-310000896622srt:EuropeMemberatr:BeautyAndHomeMember2020-01-012020-12-310000896622srt:NorthAmericaMemberatr:BeautyAndHomeMember2020-01-012020-12-310000896622srt:LatinAmericaMemberatr:BeautyAndHomeMember2020-01-012020-12-310000896622srt:AsiaMemberatr:BeautyAndHomeMember2020-01-012020-12-310000896622atr:BeautyAndHomeMember2020-01-012020-12-310000896622srt:EuropeMemberatr:FoodBeverageMember2020-01-012020-12-310000896622srt:NorthAmericaMemberatr:FoodBeverageMember2020-01-012020-12-310000896622atr:FoodBeverageMembersrt:LatinAmericaMember2020-01-012020-12-310000896622srt:AsiaMemberatr:FoodBeverageMember2020-01-012020-12-310000896622atr:FoodBeverageMember2020-01-012020-12-310000896622srt:EuropeMember2020-01-012020-12-310000896622srt:NorthAmericaMember2020-01-012020-12-310000896622srt:LatinAmericaMember2020-01-012020-12-310000896622srt:AsiaMember2020-01-012020-12-310000896622srt:EuropeMemberatr:PharmaMember2019-01-012019-12-310000896622srt:NorthAmericaMemberatr:PharmaMember2019-01-012019-12-310000896622srt:LatinAmericaMemberatr:PharmaMember2019-01-012019-12-310000896622srt:AsiaMemberatr:PharmaMember2019-01-012019-12-310000896622atr:PharmaMember2019-01-012019-12-310000896622srt:EuropeMemberatr:BeautyAndHomeMember2019-01-012019-12-310000896622srt:NorthAmericaMemberatr:BeautyAndHomeMember2019-01-012019-12-310000896622srt:LatinAmericaMemberatr:BeautyAndHomeMember2019-01-012019-12-310000896622srt:AsiaMemberatr:BeautyAndHomeMember2019-01-012019-12-310000896622atr:BeautyAndHomeMember2019-01-012019-12-310000896622srt:EuropeMemberatr:FoodBeverageMember2019-01-012019-12-310000896622srt:NorthAmericaMemberatr:FoodBeverageMember2019-01-012019-12-310000896622atr:FoodBeverageMembersrt:LatinAmericaMember2019-01-012019-12-310000896622srt:AsiaMemberatr:FoodBeverageMember2019-01-012019-12-310000896622atr:FoodBeverageMember2019-01-012019-12-310000896622srt:EuropeMember2019-01-012019-12-310000896622srt:NorthAmericaMember2019-01-012019-12-310000896622srt:LatinAmericaMember2019-01-012019-12-310000896622srt:AsiaMember2019-01-012019-12-310000896622srt:EuropeMemberatr:PharmaMember2018-01-012018-12-310000896622srt:NorthAmericaMemberatr:PharmaMember2018-01-012018-12-310000896622srt:LatinAmericaMemberatr:PharmaMember2018-01-012018-12-310000896622srt:AsiaMemberatr:PharmaMember2018-01-012018-12-310000896622atr:PharmaMember2018-01-012018-12-310000896622srt:EuropeMemberatr:BeautyAndHomeMember2018-01-012018-12-310000896622srt:NorthAmericaMemberatr:BeautyAndHomeMember2018-01-012018-12-310000896622srt:LatinAmericaMemberatr:BeautyAndHomeMember2018-01-012018-12-310000896622srt:AsiaMemberatr:BeautyAndHomeMember2018-01-012018-12-310000896622atr:BeautyAndHomeMember2018-01-012018-12-310000896622srt:EuropeMemberatr:FoodBeverageMember2018-01-012018-12-310000896622srt:NorthAmericaMemberatr:FoodBeverageMember2018-01-012018-12-310000896622atr:FoodBeverageMembersrt:LatinAmericaMember2018-01-012018-12-310000896622srt:AsiaMemberatr:FoodBeverageMember2018-01-012018-12-310000896622atr:FoodBeverageMember2018-01-012018-12-310000896622srt:EuropeMember2018-01-012018-12-310000896622srt:NorthAmericaMember2018-01-012018-12-310000896622srt:LatinAmericaMember2018-01-012018-12-310000896622srt:AsiaMember2018-01-012018-12-3100008966222021-01-012020-12-310000896622atr:PharmaMemberus-gaap:OperatingSegmentsMember2018-12-310000896622us-gaap:OperatingSegmentsMemberatr:BeautyAndHomeMember2018-12-310000896622atr:FoodBeverageMemberus-gaap:OperatingSegmentsMember2018-12-310000896622us-gaap:CorporateNonSegmentMember2018-12-310000896622atr:PharmaMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310000896622us-gaap:OperatingSegmentsMemberatr:BeautyAndHomeMember2019-01-012019-12-310000896622atr:FoodBeverageMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310000896622us-gaap:CorporateNonSegmentMember2019-01-012019-12-310000896622atr:PharmaMemberus-gaap:OperatingSegmentsMember2019-12-310000896622us-gaap:OperatingSegmentsMemberatr:BeautyAndHomeMember2019-12-310000896622atr:FoodBeverageMemberus-gaap:OperatingSegmentsMember2019-12-310000896622us-gaap:CorporateNonSegmentMember2019-12-310000896622atr:PharmaMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310000896622us-gaap:OperatingSegmentsMemberatr:BeautyAndHomeMember2020-01-012020-12-310000896622atr:FoodBeverageMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310000896622us-gaap:CorporateNonSegmentMember2020-01-012020-12-310000896622atr:PharmaMemberus-gaap:OperatingSegmentsMember2020-12-310000896622us-gaap:OperatingSegmentsMemberatr:BeautyAndHomeMember2020-12-310000896622atr:FoodBeverageMemberus-gaap:OperatingSegmentsMember2020-12-310000896622us-gaap:CorporateNonSegmentMember2020-12-310000896622us-gaap:PatentsMembersrt:WeightedAverageMember2020-01-012020-12-310000896622us-gaap:PatentsMember2020-12-310000896622us-gaap:PatentsMember2019-12-310000896622us-gaap:PatentedTechnologyMembersrt:WeightedAverageMember2020-01-012020-12-310000896622us-gaap:PatentedTechnologyMember2020-12-310000896622us-gaap:PatentedTechnologyMember2019-12-310000896622us-gaap:CustomerRelationshipsMembersrt:WeightedAverageMember2020-01-012020-12-310000896622us-gaap:CustomerRelationshipsMember2020-12-310000896622us-gaap:CustomerRelationshipsMember2019-12-310000896622us-gaap:TrademarksAndTradeNamesMembersrt:WeightedAverageMember2020-01-012020-12-310000896622us-gaap:TrademarksAndTradeNamesMember2020-12-310000896622us-gaap:TrademarksAndTradeNamesMember2019-12-310000896622srt:WeightedAverageMemberatr:LicensingAgreementsAndOtherProductMember2020-01-012020-12-310000896622atr:LicensingAgreementsAndOtherProductMember2020-12-310000896622atr:LicensingAgreementsAndOtherProductMember2019-12-310000896622srt:WeightedAverageMember2020-01-012020-12-310000896622atr:DeferredTaxAssetsSpecifiedLocationsMember2020-12-310000896622atr:DeferredTaxAssetsTaxCreditCarryforwardsStateMember2020-12-310000896622srt:MinimumMemberus-gaap:ForeignCountryMember2020-12-310000896622srt:MaximumMemberus-gaap:ForeignCountryMember2020-12-310000896622us-gaap:NotesPayableToBanksMember2020-01-012020-12-310000896622us-gaap:NotesPayableToBanksMember2020-12-310000896622us-gaap:NotesPayableToBanksMember2019-12-310000896622us-gaap:LineOfCreditMember2020-01-012020-12-310000896622us-gaap:LineOfCreditMember2020-12-310000896622us-gaap:LineOfCreditMember2019-12-310000896622us-gaap:BankOverdraftsMembersrt:MinimumMember2020-01-012020-12-310000896622srt:MaximumMemberus-gaap:BankOverdraftsMember2020-01-012020-12-310000896622us-gaap:BankOverdraftsMember2020-12-310000896622us-gaap:BankOverdraftsMember2019-12-31atr:tranche0000896622atr:FiveYearRevolvingCreditFacilityMaturingInJuly2022Member2020-01-012020-12-310000896622atr:FiveYearRevolvingCreditFacilityMaturingInJuly2022Member2020-12-31iso4217:EUR0000896622atr:FiveYearRevolvingCreditFacilityMaturingInJuly2022Member2019-12-310000896622us-gaap:RevolvingCreditFacilityMember2020-01-012020-12-310000896622us-gaap:RevolvingCreditFacilityMember2019-01-012019-12-310000896622atr:UnsecuredLinesOfCreditMember2020-01-012020-12-310000896622atr:UnsecuredLinesOfCreditMember2019-01-012019-12-310000896622us-gaap:CommercialPaperMember2020-10-012020-12-310000896622us-gaap:CommercialPaperMember2020-12-310000896622us-gaap:NotesPayableOtherPayablesMembersrt:MinimumMember2020-12-310000896622us-gaap:NotesPayableOtherPayablesMembersrt:MaximumMember2020-12-310000896622us-gaap:NotesPayableOtherPayablesMember2020-12-310000896622us-gaap:NotesPayableOtherPayablesMember2019-12-310000896622atr:SeniorUnsecuredNotes3.2PercentDue2022Member2020-12-310000896622atr:SeniorUnsecuredNotes3.2PercentDue2022Member2019-12-310000896622us-gaap:NotesPayableToBanksMember2020-12-310000896622us-gaap:NotesPayableToBanksMember2019-12-310000896622atr:SeniorUnsecuredNotes3.5PercentDue2023Member2020-12-310000896622atr:SeniorUnsecuredNotes3.5PercentDue2023Member2019-12-310000896622atr:SeniorUnsecuredNotes0.98DueIn2023Member2020-12-310000896622atr:SeniorUnsecuredNotes0.98DueIn2023Member2019-12-310000896622atr:SeniorUnsecuredNotes3.4PercentDue2024Member2020-12-310000896622atr:SeniorUnsecuredNotes3.4PercentDue2024Member2019-12-310000896622atr:SeniorUnsecuredNotes3.5PercentDue2024Member2020-12-310000896622atr:SeniorUnsecuredNotes3.5PercentDue2024Member2019-12-310000896622atr:SeniorUnsecuredNotes1.17DueIn2024Member2020-12-310000896622atr:SeniorUnsecuredNotes1.17DueIn2024Member2019-12-310000896622atr:SeniorUnsecuredNotes3.6PercentDue2025Member2020-12-310000896622atr:SeniorUnsecuredNotes3.6PercentDue2025Member2019-12-310000896622atr:SeniorUnsecuredNotes3.6PercentDue2026Member2020-12-310000896622atr:SeniorUnsecuredNotes3.6PercentDue2026Member2019-12-310000896622srt:MaximumMember2020-12-310000896622srt:MinimumMember2020-12-310000896622srt:MinimumMember2020-01-012020-12-310000896622srt:MaximumMember2020-01-012020-12-310000896622country:US2019-12-310000896622country:US2018-12-310000896622us-gaap:ForeignPlanMember2019-12-310000896622us-gaap:ForeignPlanMember2018-12-310000896622country:US2020-01-012020-12-310000896622country:US2019-01-012019-12-310000896622us-gaap:ForeignPlanMember2020-01-012020-12-310000896622us-gaap:ForeignPlanMember2019-01-012019-12-310000896622country:US2020-12-310000896622us-gaap:ForeignPlanMember2020-12-310000896622country:US2018-01-012018-12-310000896622us-gaap:ForeignPlanMember2018-01-012018-12-310000896622us-gaap:DefinedBenefitPlanEquitySecuritiesMembercountry:US2020-12-310000896622us-gaap:DefinedBenefitPlanEquitySecuritiesMembercountry:US2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2019-12-310000896622country:USus-gaap:FixedIncomeFundsMember2020-12-310000896622country:USus-gaap:FixedIncomeFundsMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FixedIncomeFundsMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FixedIncomeFundsMember2019-12-310000896622us-gaap:CorporateDebtSecuritiesMembercountry:US2020-12-310000896622us-gaap:CorporateDebtSecuritiesMembercountry:US2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:CorporateDebtSecuritiesMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:CorporateDebtSecuritiesMember2019-12-310000896622country:USatr:InfrastructureMember2020-12-310000896622country:USatr:InfrastructureMember2019-12-310000896622us-gaap:ForeignPlanMemberatr:InfrastructureMember2020-12-310000896622us-gaap:ForeignPlanMemberatr:InfrastructureMember2019-12-310000896622country:USus-gaap:HedgeFundsMember2020-12-310000896622country:USus-gaap:HedgeFundsMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:HedgeFundsMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:HedgeFundsMember2019-12-310000896622country:USus-gaap:MoneyMarketFundsMember2020-12-310000896622country:USus-gaap:MoneyMarketFundsMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:MoneyMarketFundsMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:MoneyMarketFundsMember2019-12-310000896622country:USatr:InvestmentFundsMember2020-12-310000896622country:USatr:InvestmentFundsMember2019-12-310000896622us-gaap:ForeignPlanMemberatr:InvestmentFundsMember2020-12-310000896622us-gaap:ForeignPlanMemberatr:InvestmentFundsMember2019-12-310000896622us-gaap:RealEstateFundsMembercountry:US2020-12-310000896622us-gaap:RealEstateFundsMembercountry:US2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:RealEstateFundsMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:RealEstateFundsMember2019-12-310000896622country:USatr:FixedIncomeSecuritiesAndInfrastructureMember2020-12-310000896622us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622currency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622currency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Membercurrency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Membercurrency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMembercurrency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMembercurrency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Membercurrency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembercurrency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:UScurrency:EURus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Membercountry:UScurrency:EURus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:UScurrency:EURus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:UScurrency:EURus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercurrency:EURus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Membercurrency:EURus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercurrency:EURus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercurrency:EURus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberatr:OtherCurrencyMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberatr:OtherCurrencyMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberatr:OtherCurrencyMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberatr:OtherCurrencyMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberatr:OtherCurrencyMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberatr:OtherCurrencyMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberatr:OtherCurrencyMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberatr:OtherCurrencyMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:DefinedBenefitPlanEquitySecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622country:USus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622country:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMember2020-12-310000896622us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMember2020-12-310000896622us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMember2020-12-310000896622us-gaap:CorporateDebtSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:CorporateBondSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622country:USatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:FairValueInputsLevel1Membercountry:USatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Membercountry:USatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Membercountry:USatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622country:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Memberus-gaap:EquityFundsMember2020-12-310000896622us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquityFundsMember2020-12-310000896622us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquityFundsMember2020-12-310000896622us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquityFundsMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Memberus-gaap:EquityFundsMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquityFundsMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquityFundsMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquityFundsMember2020-12-310000896622us-gaap:BondsMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:BondsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:BondsMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:BondsMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:BondsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:BondsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:BondsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:BondsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622country:USatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:FairValueInputsLevel1Membercountry:USatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Membercountry:USatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Membercountry:USatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622country:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622country:USus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622currency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622currency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Membercurrency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Membercurrency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMembercurrency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMembercurrency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Membercurrency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembercurrency:USDus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:UScurrency:EURus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Membercountry:UScurrency:EURus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:UScurrency:EURus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercountry:UScurrency:EURus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercurrency:EURus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Membercurrency:EURus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercurrency:EURus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMembercurrency:EURus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberatr:OtherCurrencyMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberatr:OtherCurrencyMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberatr:OtherCurrencyMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberatr:OtherCurrencyMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberatr:OtherCurrencyMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberatr:OtherCurrencyMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberatr:OtherCurrencyMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberatr:OtherCurrencyMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:DefinedBenefitPlanEquitySecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsLargeCapMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsSmallCapMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622country:USus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622country:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMember2019-12-310000896622us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMember2019-12-310000896622us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FixedIncomeFundsMember2019-12-310000896622us-gaap:CorporateDebtSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:CorporateBondSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622country:USatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:FairValueInputsLevel1Membercountry:USatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Membercountry:USatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Membercountry:USatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberatr:InvestmentFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622country:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Memberus-gaap:EquityFundsMember2019-12-310000896622us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquityFundsMember2019-12-310000896622us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquityFundsMember2019-12-310000896622us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquityFundsMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Memberus-gaap:EquityFundsMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquityFundsMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquityFundsMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquityFundsMember2019-12-310000896622us-gaap:BondsMembercountry:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:BondsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:BondsMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:BondsMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:BondsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:BondsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:BondsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:BondsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622country:USatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:FairValueInputsLevel1Membercountry:USatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Membercountry:USatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Membercountry:USatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberatr:MutualFundsDiversifiedMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622country:USus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel12And3Member2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622country:USus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMembercountry:US2020-12-310000896622us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMembercountry:US2019-12-310000896622country:USsrt:MaximumMember2020-01-012020-12-310000896622us-gaap:SubsequentEventMembercountry:USsrt:MaximumMember2021-01-012021-12-310000896622us-gaap:AccumulatedTranslationAdjustmentMember2017-12-310000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2017-12-310000896622us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2017-12-310000896622us-gaap:AccumulatedTranslationAdjustmentMember2018-01-012018-12-310000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-01-012018-12-310000896622us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-01-012018-12-310000896622us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-12-310000896622us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-12-310000896622us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-12-310000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-12-310000896622us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-12-310000896622us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310000896622us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310000896622us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-12-310000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-12-310000896622us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-12-310000896622us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000896622us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2020-01-012020-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2019-01-012019-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2018-01-012018-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2020-01-012020-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2019-01-012019-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2018-01-012018-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-01-012018-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:TreasuryLockMember2020-01-012020-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:TreasuryLockMember2019-01-012019-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:TreasuryLockMember2018-01-012018-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2020-01-012020-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2019-01-012019-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2018-01-012018-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:CurrencySwapMember2020-01-012020-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:CurrencySwapMember2019-01-012019-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:CurrencySwapMember2018-01-012018-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-01-012018-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310000896622us-gaap:NotesPayableToBanksMember2017-07-012017-09-300000896622us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMember2017-07-200000896622us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMember2020-01-012020-12-310000896622us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMember2019-01-012019-12-310000896622us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2020-12-310000896622us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMember2020-12-310000896622us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:ForeignExchangeContractMember2020-12-310000896622us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2020-12-310000896622us-gaap:ForeignExchangeContractMember2020-12-310000896622us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2020-12-310000896622us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2019-12-310000896622us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:ForeignExchangeContractMember2019-12-310000896622us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CrossCurrencyInterestRateContractMember2020-12-310000896622us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:CrossCurrencyInterestRateContractMember2020-12-310000896622us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CrossCurrencyInterestRateContractMember2019-12-310000896622us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:CrossCurrencyInterestRateContractMember2019-12-310000896622us-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000896622us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2020-12-310000896622us-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000896622us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2019-12-310000896622us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2020-12-310000896622us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2019-12-310000896622us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2019-12-310000896622us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2020-12-310000896622us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2020-12-310000896622us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2019-12-310000896622us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2019-12-310000896622us-gaap:InterestRateSwapMember2020-01-012020-12-310000896622us-gaap:InterestRateSwapMember2019-01-012019-12-310000896622us-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2020-01-012020-12-310000896622us-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2019-01-012019-12-310000896622us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2020-01-012020-12-310000896622us-gaap:CurrencySwapMember2020-01-012020-12-310000896622us-gaap:CurrencySwapMember2019-01-012019-12-310000896622us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2020-01-012020-12-310000896622us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2019-01-012019-12-310000896622us-gaap:CashFlowHedgingMemberus-gaap:CurrencySwapMember2020-01-012020-12-310000896622us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2020-01-012020-12-310000896622us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2019-01-012019-12-310000896622us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000896622us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberatr:FusionMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberatr:FusionMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberatr:NobleMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberatr:NobleMember2019-12-310000896622us-gaap:FairValueInputsLevel3Memberatr:GatewayAnalyticalMember2020-12-310000896622us-gaap:FairValueInputsLevel3Memberatr:GatewayAnalyticalMember2019-12-310000896622us-gaap:FairValueInputsLevel3Member2020-12-310000896622us-gaap:FairValueInputsLevel3Member2019-12-310000896622atr:TaxAssessmentMembercountry:BR2020-12-310000896622country:BR2017-01-012017-03-310000896622country:BR2020-01-012020-12-310000896622country:BR2019-01-012019-12-310000896622country:BR2020-12-310000896622us-gaap:ReductionInTaxesMembercountry:BR2020-06-300000896622us-gaap:ReductionInTaxesMemberus-gaap:CostOfSalesMembercountry:BR2020-06-300000896622us-gaap:ReductionInTaxesMembercountry:BR2019-03-310000896622us-gaap:ReductionInTaxesMemberus-gaap:CostOfSalesMembercountry:BR2019-03-310000896622us-gaap:InterestIncomeMemberus-gaap:ReductionInTaxesMembercountry:BR2019-03-310000896622us-gaap:ReductionInTaxesMembercountry:BR2018-12-310000896622us-gaap:ReductionInTaxesMembersrt:MinimumMembercountry:BR2020-12-310000896622srt:MaximumMemberus-gaap:ReductionInTaxesMembercountry:BR2020-12-310000896622atr:TaxAssessmentMembercountry:BR2019-12-310000896622atr:TaxAssessmentInterestMembercountry:BR2019-12-310000896622atr:TaxAssessmentPenalitesMembercountry:BR2019-12-310000896622us-gaap:IndemnificationGuaranteeMember2020-12-310000896622atr:StockRepurchaseProgramApril182019Member2019-04-180000896622us-gaap:CommonStockMemberatr:StockAwardPlansMember2020-01-012020-12-310000896622us-gaap:CommonStockMemberatr:StockAwardPlansMember2019-01-012019-12-310000896622us-gaap:CommonStockMemberatr:StockAwardPlansMember2018-01-012018-12-310000896622us-gaap:TreasuryStockMemberatr:StockAwardPlansMember2020-01-012020-12-310000896622us-gaap:TreasuryStockMemberatr:StockAwardPlansMember2019-01-012019-12-310000896622us-gaap:TreasuryStockMemberatr:StockAwardPlansMember2018-01-012018-12-310000896622atr:DirectorStockOptionPlansMemberus-gaap:CommonStockMember2020-01-012020-12-310000896622atr:DirectorStockOptionPlansMemberus-gaap:CommonStockMember2019-01-012019-12-310000896622atr:DirectorStockOptionPlansMemberus-gaap:CommonStockMember2018-01-012018-12-310000896622atr:StockAwardPlansMemberatr:RestrictedStockUnitsTimeBasedMember2020-01-012020-12-310000896622atr:RestrictedStockUnitsPerformanceBasedMemberatr:StockAwardPlansMember2020-01-012020-12-310000896622atr:DirectorStockOptionPlansMemberus-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310000896622atr:RestrictedStockUnitsPerformanceBasedMemberatr:StockAwardPlansMember2019-01-012019-12-310000896622atr:RestrictedStockUnitsPerformanceBasedMemberatr:StockAwardPlansMember2018-01-012018-12-310000896622atr:RestrictedStockUnitsTimeBasedMember2019-12-310000896622atr:RestrictedStockUnitsPerformanceBasedMember2019-12-310000896622atr:RestrictedStockUnitsTimeBasedMember2020-01-012020-12-310000896622atr:RestrictedStockUnitsPerformanceBasedMember2020-01-012020-12-310000896622atr:RestrictedStockUnitsTimeBasedMember2020-12-310000896622atr:RestrictedStockUnitsPerformanceBasedMember2020-12-310000896622atr:DirectorStockOptionPlansMemberatr:RestrictedStockUnitsTimeBasedMember2020-01-012020-12-310000896622us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310000896622us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310000896622us-gaap:RestrictedStockUnitsRSUMember2018-01-012018-12-310000896622us-gaap:RestrictedStockUnitsRSUMember2020-12-310000896622us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000896622atr:StockAwardPlansMemberus-gaap:EmployeeStockOptionMember2018-01-012018-12-310000896622atr:StockAwardPlansMemberus-gaap:EmployeeStockOptionMember2019-12-310000896622atr:DirectorStockOptionPlansMemberus-gaap:EmployeeStockOptionMember2019-12-310000896622atr:StockAwardPlansMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310000896622atr:DirectorStockOptionPlansMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310000896622atr:StockAwardPlansMemberus-gaap:EmployeeStockOptionMember2020-12-310000896622atr:DirectorStockOptionPlansMemberus-gaap:EmployeeStockOptionMember2020-12-310000896622atr:StockAwardPlansMemberus-gaap:EmployeeStockOptionMember2019-01-012019-12-310000896622atr:DirectorStockOptionPlansMemberus-gaap:EmployeeStockOptionMember2019-01-012019-12-310000896622atr:DirectorStockOptionPlansMemberus-gaap:EmployeeStockOptionMember2018-01-012018-12-310000896622atr:SellingResearchAndDevelopmentAndAdministrativeExpensesMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310000896622atr:SellingResearchAndDevelopmentAndAdministrativeExpensesMemberus-gaap:EmployeeStockOptionMember2019-01-012019-12-310000896622atr:SellingResearchAndDevelopmentAndAdministrativeExpensesMemberus-gaap:EmployeeStockOptionMember2018-01-012018-12-310000896622us-gaap:CostOfSalesMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310000896622us-gaap:CostOfSalesMemberus-gaap:EmployeeStockOptionMember2019-01-012019-12-310000896622us-gaap:CostOfSalesMemberus-gaap:EmployeeStockOptionMember2018-01-012018-12-310000896622us-gaap:EmployeeStockOptionMember2019-01-012019-12-310000896622us-gaap:EmployeeStockOptionMember2018-01-012018-12-310000896622us-gaap:EmployeeStockOptionMember2020-12-31atr:segment0000896622atr:PharmaMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310000896622us-gaap:OperatingSegmentsMemberatr:BeautyAndHomeMember2018-01-012018-12-310000896622atr:FoodBeverageMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310000896622us-gaap:OperatingSegmentsMember2020-01-012020-12-310000896622us-gaap:OperatingSegmentsMember2019-01-012019-12-310000896622us-gaap:OperatingSegmentsMember2018-01-012018-12-310000896622us-gaap:IntersegmentEliminationMemberatr:PharmaMember2020-01-012020-12-310000896622us-gaap:IntersegmentEliminationMemberatr:PharmaMember2019-01-012019-12-310000896622us-gaap:IntersegmentEliminationMemberatr:PharmaMember2018-01-012018-12-310000896622us-gaap:IntersegmentEliminationMemberatr:BeautyAndHomeMember2020-01-012020-12-310000896622us-gaap:IntersegmentEliminationMemberatr:BeautyAndHomeMember2019-01-012019-12-310000896622us-gaap:IntersegmentEliminationMemberatr:BeautyAndHomeMember2018-01-012018-12-310000896622atr:FoodBeverageMemberus-gaap:IntersegmentEliminationMember2020-01-012020-12-310000896622atr:FoodBeverageMemberus-gaap:IntersegmentEliminationMember2019-01-012019-12-310000896622atr:FoodBeverageMemberus-gaap:IntersegmentEliminationMember2018-01-012018-12-310000896622us-gaap:IntersegmentEliminationMember2020-01-012020-12-310000896622us-gaap:IntersegmentEliminationMember2019-01-012019-12-310000896622us-gaap:IntersegmentEliminationMember2018-01-012018-12-310000896622us-gaap:CorporateAndOtherMember2020-01-012020-12-310000896622us-gaap:CorporateAndOtherMember2019-01-012019-12-310000896622us-gaap:CorporateAndOtherMember2018-01-012018-12-310000896622atr:PharmaMember2020-12-310000896622atr:PharmaMember2019-12-310000896622atr:PharmaMember2018-12-310000896622atr:BeautyAndHomeMember2020-12-310000896622atr:BeautyAndHomeMember2019-12-310000896622atr:BeautyAndHomeMember2018-12-310000896622atr:FoodBeverageMember2020-12-310000896622atr:FoodBeverageMember2019-12-310000896622atr:FoodBeverageMember2018-12-310000896622us-gaap:CorporateAndOtherMember2020-12-310000896622us-gaap:CorporateAndOtherMember2019-12-310000896622us-gaap:CorporateAndOtherMember2018-12-310000896622country:US2020-01-012020-12-310000896622country:US2019-01-012019-12-310000896622country:US2018-01-012018-12-310000896622country:FR2020-01-012020-12-310000896622country:FR2019-01-012019-12-310000896622country:FR2018-01-012018-12-310000896622country:DE2020-01-012020-12-310000896622country:DE2019-01-012019-12-310000896622country:DE2018-01-012018-12-310000896622country:IT2020-01-012020-12-310000896622country:IT2019-01-012019-12-310000896622country:IT2018-01-012018-12-310000896622atr:OtherEuropeMember2020-01-012020-12-310000896622atr:OtherEuropeMember2019-01-012019-12-310000896622atr:OtherEuropeMember2018-01-012018-12-310000896622atr:OtherForeignCountriesMember2020-01-012020-12-310000896622atr:OtherForeignCountriesMember2019-01-012019-12-310000896622atr:OtherForeignCountriesMember2018-01-012018-12-310000896622country:US2020-12-310000896622country:US2019-12-310000896622country:US2018-12-310000896622country:FR2020-12-310000896622country:FR2019-12-310000896622country:FR2018-12-310000896622country:DE2020-12-310000896622country:DE2019-12-310000896622country:DE2018-12-310000896622country:IT2020-12-310000896622country:IT2019-12-310000896622country:IT2018-12-310000896622atr:OtherEuropeMember2020-12-310000896622atr:OtherEuropeMember2019-12-310000896622atr:OtherEuropeMember2018-12-310000896622srt:EuropeMember2020-12-310000896622srt:EuropeMember2019-12-310000896622srt:EuropeMember2018-12-310000896622atr:OtherForeignCountriesMember2020-12-310000896622atr:OtherForeignCountriesMember2019-12-310000896622atr:OtherForeignCountriesMember2018-12-310000896622us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310000896622us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310000896622us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310000896622atr:FusionPackagingMember2020-04-010000896622atr:FusionPackagingMember2020-04-012020-04-010000896622atr:FusionPackagingMember2020-10-012020-12-310000896622atr:FusionPackagingMember2020-12-310000896622atr:FusionPackagingMember2020-07-012020-09-300000896622atr:FusionPackagingMember2020-01-012020-12-310000896622atr:NobleMember2019-10-310000896622atr:NobleMember2019-10-312019-10-310000896622atr:NobleMember2020-12-310000896622atr:NobleMember2019-12-310000896622atr:NobleMember2020-01-012020-03-310000896622atr:NanopharmMember2019-06-052019-06-050000896622atr:NanopharmMember2019-06-050000896622atr:GatewayAnalyticalMember2019-05-312019-05-310000896622atr:GatewayAnalyticalMember2019-05-310000896622atr:GatewayAnalyticalMember2020-04-012020-06-300000896622atr:GatewayAnalyticalMember2020-07-012020-09-300000896622atr:Acquisitions2020Member2020-01-012020-12-310000896622atr:Acquisitions2019Member2019-01-012019-12-310000896622atr:Acquisitions2020Member2020-12-310000896622atr:Acquisitions2019Member2019-12-310000896622us-gaap:PatentedTechnologyMemberatr:Acquisitions2020Member2020-01-012020-12-310000896622us-gaap:PatentedTechnologyMemberatr:Acquisitions2020Member2020-12-310000896622us-gaap:PatentedTechnologyMemberatr:Acquisitions2019Member2019-01-012019-12-310000896622us-gaap:PatentedTechnologyMemberatr:Acquisitions2019Member2019-12-310000896622atr:Acquisitions2020Memberus-gaap:CustomerRelationshipsMember2020-01-012020-12-310000896622atr:Acquisitions2020Memberus-gaap:CustomerRelationshipsMember2020-12-310000896622atr:Acquisitions2019Memberus-gaap:CustomerRelationshipsMember2019-01-012019-12-310000896622atr:Acquisitions2019Memberus-gaap:CustomerRelationshipsMember2019-12-310000896622us-gaap:TrademarksAndTradeNamesMemberatr:Acquisitions2020Member2020-01-012020-12-310000896622us-gaap:TrademarksAndTradeNamesMemberatr:Acquisitions2020Member2020-12-310000896622atr:Acquisitions2019Memberus-gaap:TrademarksAndTradeNamesMember2019-01-012019-12-310000896622atr:Acquisitions2019Memberus-gaap:TrademarksAndTradeNamesMember2019-12-310000896622atr:Acquisitions2020Memberatr:LicensingAgreementsAndOtherProductMember2020-01-012020-12-310000896622atr:Acquisitions2020Memberatr:LicensingAgreementsAndOtherProductMember2020-12-310000896622atr:Acquisitions2019Memberatr:LicensingAgreementsAndOtherProductMember2019-01-012019-12-310000896622atr:Acquisitions2019Memberatr:LicensingAgreementsAndOtherProductMember2019-12-310000896622atr:Acquisitions2020Memberatr:BeautyAndHomeMember2020-12-310000896622atr:Acquisitions2019Memberatr:PharmaMember2019-12-310000896622atr:FusionPackagingMember2019-01-012019-12-310000896622atr:FusionPackagingMember2018-01-012018-12-310000896622atr:CoheroHealthIncMember2020-10-162020-10-160000896622atr:BapcoClosuresHoldingLimitedMember2019-08-020000896622atr:BapcoClosuresHoldingLimitedMember2019-08-022019-08-020000896622atr:BapcoClosuresHoldingLimitedMember2018-12-310000896622atr:BtyMember2020-12-310000896622atr:BtyMember2019-12-310000896622atr:SonmolMember2020-12-310000896622atr:SonmolMember2019-12-310000896622atr:KaliCareMember2020-12-310000896622atr:KaliCareMember2019-12-310000896622atr:DesotecGmbhMember2020-12-310000896622atr:DesotecGmbhMember2019-12-310000896622atr:PurecycleMember2020-12-310000896622atr:PurecycleMember2019-12-310000896622atr:LoopMember2020-12-310000896622atr:LoopMember2019-12-310000896622atr:OthersMember2020-12-310000896622atr:OthersMember2019-12-310000896622atr:SonmolMember2020-04-012020-04-010000896622atr:SonmolMember2020-04-010000896622atr:BtyMember2020-01-010000896622atr:BtyMember2020-01-012020-01-010000896622us-gaap:CallOptionMembersrt:MinimumMemberatr:BtyMember2020-01-010000896622srt:MaximumMemberus-gaap:CallOptionMemberatr:BtyMember2020-01-010000896622atr:KaliCareMember2017-01-012017-12-310000896622atr:KaliCareMember2017-12-310000896622atr:KaliCareMember2017-01-012020-12-310000896622atr:DesotecGmbhMember2009-01-012009-12-310000896622atr:DesotecGmbhMember2009-12-310000896622atr:PurecycleMember2020-01-012020-12-310000896622atr:BusinessTransformationPlanMember2020-01-012020-12-310000896622atr:BusinessTransformationPlanMember2019-01-012019-12-310000896622atr:BusinessTransformationPlanMember2018-01-012018-12-310000896622atr:BusinessTransformationPlanMember2020-12-310000896622atr:BusinessTransformationPlanMemberus-gaap:EmployeeSeveranceMember2019-12-310000896622atr:BusinessTransformationPlanMemberus-gaap:EmployeeSeveranceMember2020-01-012020-12-310000896622atr:BusinessTransformationPlanMemberus-gaap:EmployeeSeveranceMember2020-12-310000896622atr:BusinessTransformationPlanMemberatr:OtherRestructuringCostsMember2019-12-310000896622atr:BusinessTransformationPlanMemberatr:OtherRestructuringCostsMember2020-01-012020-12-310000896622atr:BusinessTransformationPlanMemberatr:OtherRestructuringCostsMember2020-12-310000896622atr:BusinessTransformationPlanMember2019-12-3100008966222020-01-012020-03-3100008966222020-04-012020-06-3000008966222020-07-012020-09-3000008966222020-10-012020-12-3100008966222019-01-012019-03-3100008966222019-04-012019-06-3000008966222019-07-012019-09-3000008966222019-10-012019-12-310000896622atr:AllowanceForCreditLossCurrentMember2019-12-310000896622atr:AllowanceForCreditLossCurrentMember2020-01-012020-12-310000896622atr:AllowanceForCreditLossCurrentMember2020-12-310000896622us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-12-310000896622us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-01-012020-12-310000896622us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-12-310000896622atr:AllowanceForCreditLossCurrentMember2018-12-310000896622atr:AllowanceForCreditLossCurrentMember2019-01-012019-12-310000896622us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-12-310000896622us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-01-012019-12-310000896622atr:AllowanceForCreditLossCurrentMember2017-12-310000896622atr:AllowanceForCreditLossCurrentMember2018-01-012018-12-310000896622us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2017-12-310000896622us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-01-012018-12-31
Table of Contents
United States Securities and Exchange Commission
Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM_____TO_____
COMMISSION FILE NUMBER 1-11846
atr-20201231_g1.jpg
AptarGroup, Inc.
Delaware36-3853103
265 EXCHANGE DRIVE, SUITE 100, CRYSTAL LAKE, IL 60014
815-477-0424
Securities Registered Pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, $.01 par valueATRNew York Stock Exchange
Securities Registered Pursuant to Section 12(g) of the Act:
NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes
No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes
No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes
No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes
No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes
No
The aggregate market value of the common stock held by non-affiliates as of June 30, 2020 was $7,230,606,494.
The number of shares outstanding of common stock, as of February 15, 2021, was 65,163,222 shares.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the definitive Proxy Statement to be delivered to stockholders in connection with the Annual Meeting of Stockholders to be held May 5, 2021 are incorporated by reference into Part III of this report.



Table of Contents
AptarGroup, Inc.
FORM 10-K
For the Year Ended December 31, 2020
INDEX
Page
i/ATR
2020 Form 10-K

Table of Contents
PART I
ITEM 1. BUSINESS
WHO ARE WE AND WHAT DO WE DO
Aptar is a global leader in the design and manufacturing of a broad range of innovative drug delivery and consumer product dispensing, sealing and active packaging solutions and services for the prescription drug, consumer health care, injectables, active packaging, beauty, personal care, home care, food and beverage markets. Aptar uses insights, design, engineering and science to create dosing, dispensing, and protective packaging technologies for many of the world's leading brands, in turn, making a meaningful difference in the lives, looks, health and homes of people around the world. Aptar is headquartered in Crystal Lake, Illinois and has approximately 13,000 dedicated employees in 20 different countries. For more information, visit www.aptar.com.
Our business was started in the late 1940’s, manufacturing and selling aerosol valves in the United States, and has grown primarily through acquisitions and internal expansion. In this report, we may refer to AptarGroup, Inc. and its subsidiaries as “AptarGroup”, “Aptar” or the “Company”.
We have manufacturing facilities located throughout the world including North America, Europe, Asia and South America. We have approximately 6,000 customers with no single customer or group of affiliated customers accounting for greater than 5% of our 2020 Net Sales.
Consumers’ preference for convenience and product differentiation through drug delivery and packaging design and function are important to our customers and they have converted many of their packages from non-dispensing formats to dispensing systems that offer enhanced shelf appeal, convenience, cleanliness and accuracy of dosage.
We partner with our customers by providing innovative delivery systems and a suite of comprehensive services to help them succeed. While we offer a wide variety of services and products, our primary products are dispensing pumps, closures, aerosol valves, elastomeric primary packaging components and active packaging solutions.
Dispensing pumps are finger-actuated dispensing systems that dispense a spray or lotion from non-pressurized containers. The style of pump used depends largely on the nature of the product being dispensed, from small, fine mist pumps used with pharmaceutical products and perfume to lotion pumps for more viscous formulas.
Closures are primarily dispensing closures but to a lesser degree can include non-dispensing closures. Dispensing closures are plastic caps that allow a product to be dispensed without removing the cap.
Aerosol valves dispense product from pressurized containers. The majority of the aerosol valves that we sell are metered dose continuous spray valves, with the balance being bag-on valve and continuous spray valves.
We also manufacture and sell elastomeric primary packaging components. These components are used in the injectables market. Products include stoppers for infusion, antibiotic, lyophilization and diagnostic vials. Our elastomeric components also include pre-filled syringe components, such as plungers, needle shields, tip caps and cartridges, as well as dropper bulbs and syringe plungers.
We provide active packaging solutions via our material science technology which maintains the integrity of the container contents, extends shelf-life, controls moisture and reduces oxygenation. Our active packaging solutions remove gasses from the interior of the package environment and remove odor and other harmful contaminants.
During 2020 and 2019, we acquired several companies to strengthen and broaden our portfolio, including the following business combinations and asset purchases:
-    October 2020 – Cohero Health, Inc. ("Cohero Health") asset purchase for cash paid at close of $2.4 million.
-    April 2020 – Fusion Packaging, Inc. ("Fusion") for cash paid at close of approximately $163.8 million (net of $1.0 million of cash acquired) and contingent consideration liability due to sellers related to earn-out.
-    October 2019 – Noble International Holdings, Inc., Genia Medical, Inc. and JBCB Holdings, LLC (collectively referred to as “Noble”) for cash paid at close of approximately $62.3 million (net of $1.6 million of cash acquired) and contingent consideration liability due to sellers related to earn-out.
-    August 2019 – Bapco Closures Holdings Limited ("Bapco") for cash paid at close of $3.8 million (net of $2.9 million of cash acquired).
-    June 2019 – Nanopharm Ltd. (“Nanopharm”) for cash paid at close of approximately $38.1 million (net of $1.8 million of cash acquired).
-    May 2019 – Gateway Analytical LLC (“Gateway”) for cash paid at close of approximately $7.0 million and contingent consideration liability due to sellers related to earn-out.

1/ATR
2020 Form 10-K

Table of Contents
To further broaden our portfolio, during 2020 and 2019, we also invested in several equity investments, including:
-    April 2020 – We acquired 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as "Sonmol") for $5 million.
-    January 2020 – We acquired 49% of the equity interests in three related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”) for $32 million.     
-    August 2019 – We made two preferred equity investments in sustainability companies Loop and PureCycle Technologies (“PureCycle”) for an aggregate amount of $3.5 million. In July 2020 and September 2020 we invested an additional $1.4 million in these two equity investments and also received $333 thousand of equity in PureCycle in exchange for a dedicated resource.
Refer to Note 19- Acquisitions and Note 20 - Investments in Equity Securities in Item 8 – Consolidated Financial Statements and Supplementary Data for further details on acquisition and related investment activities.
AVAILABLE INFORMATION
Our periodic and current reports, and any amendments to those reports, are available, free of charge, through a link on the Investors page of our website (www.aptar.com), as soon as reasonably practicable after the material is electronically filed with, or furnished to, the Securities and Exchange Commission (“SEC”). These filings are also available to the public over the Internet at the SEC’s website (www.sec.gov).
Also posted on our website are the charters for our Audit, Management Development and Compensation, Governance and Executive Committees, our Governance Principles, our Code of Conduct, our Director Independence Standards and our Conflict Minerals Statement. Within the time period required by the SEC and the New York Stock Exchange (“NYSE”), we will post on our website any amendment or waiver to the Code of Business Conduct & Ethics applicable to any executive officer or director. The information provided on our website is not part of this report and is therefore not incorporated herein by reference.
OUR STRATEGY
We seek to enhance our position as a leading global provider of innovative drug delivery and consumer product dispensing, sealing, active packaging solutions and services to deliver increased value to our customers and stockholders through strategic focus and execution in the following areas:
(i)Focus on Organic Growth: We are focused on accelerating our top line growth with added emphasis on high growth economies. Accordingly, we are creating empowered, regional, cross-functional profit and loss (“P&L”) teams who are fully accountable to drive profitable growth.
(ii)Focus on Talent and Leadership: Execution of our strategy requires a talented, motivated, diverse, global team. We have a focused talent acquisition and development strategy to ensure our teams have the right skills to execute our strategy.
(iii)Excellence in Core Business Functions: We have established three pillars of functional excellence to ensure we perform at best in class levels in the core functions of any manufacturing business, namely “innovate,” “produce” and “sell,” and that our business teams are supported in the areas of Innovation, Operations and Commercial Excellence.
(iv)Successful Transformation: To strengthen our performance and deepen our position as a true market shaper, we continually evaluate our business. In late 2017, we launched a comprehensive business transformation plan within our Beauty + Home segment and our key corporate support functions. While the global COVID-19 pandemic and other headwinds have negatively impacted volumes in our Beauty + Home segment and deferred some initiatives past our original 3 year timeline, we have continued focus on transforming our Beauty + Home segment by adding capabilities in Asia and capitalizing on fast growing application fields within the segment.
(v)Partnerships and Acquisitions: We will continue to focus on growing the Company through appropriate business acquisition opportunities as well as developing partnerships to expand the scope of our technologies, geographic presence and product offerings.
Facilitating the execution of our strategy are our core values, which dictate how we interact internally and externally with our employees, customers, suppliers and all stakeholders.
2/ATR
2020 Form 10-K

Table of Contents
DESCRIPTION OF OUR REPORTING SEGMENTS
INFORMATION ABOUT SEGMENTS
Our organizational structure consists of three market-focused business segments: Pharma, Beauty + Home and Food + Beverage. This is a strategic structure which allows us to be more closely aligned with our customers and the markets in which they operate. We primarily sell our products and services through our own sales force to pharmaceutical, health care, beauty, personal care, home care, food and beverage marketers. To a limited extent, we use independent representatives and distributors to increase our reach to smaller customers and export markets.
Operations that sell dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables and active packaging markets form the Pharma segment. Operations that sell dispensing systems and sealing solutions primarily to the beauty, personal care and home care markets form the Beauty + Home segment. Operations that sell dispensing systems and sealing solutions to the food and beverage markets form the Food + Beverage segment. Each of these three business segments is described more fully below.
PHARMA
The Pharma segment is our largest segment in terms of profitability, accounting for 68% of our Adjusted EBITDA excluding non-allocated corporate costs, and is our second largest segment in terms of net sales and total assets, accounting for 42% and 39% of our Net Sales and Total Assets, respectively, in 2020. We believe we are a leading supplier of nasal drug delivery spray pumps and metered dose inhaler valves (“MDIs”) to the pharmaceutical and health care markets worldwide and we are an important supplier of elastomer for injectable primary packaging components worldwide. Characteristics of this market include (i) governmental regulation of our pharmaceutical customers, (ii) contaminant-controlled manufacturing environments and (iii) a significant amount of time and research from initially working with pharmaceutical companies at the molecular development stage of a medication through the eventual distribution to the market. We have clean-room manufacturing facilities in Argentina, China, France, Germany, India, Switzerland and the United States. We believe that providing value-added, convenient drug delivery and dispensing systems will continue to offer opportunities for our business. In addition, we believe there are opportunities for growth in the over-the-counter and generic pharmaceutical categories.
Prescription Drug. Sales to the prescription drug market accounted for approximately 46% of the segment’s total net sales in 2020. Pumps sold to the prescription drug market deliver medications nasally, orally or topically. Currently the majority of our pumps sold are for nasal allergy treatments. Sales of pumps to deliver prescription allergy medicine that is now available over-the-counter remains part of our prescription drug division. This could provide us with growth opportunities as the movement to over-the-counter availability allows consumers easier access to these types of treatments. Our nasal pumps and unit dose and bidose devices are also used to deliver pain management and central nervous system therapies.
MDIs are used for dispensing precise amounts of aerosolized medication. This technology allows medication to be broken up into very fine particles, which enables the drug to be delivered typically via the pulmonary route. Currently the majority of our MDIs sold are used for respiratory ailments such as asthma and COPD (chronic obstructive pulmonary disease).
We continue to develop new drug delivery and dispensing systems and accessories in this segment. For example, we provide single dose delivery devices suitable for central nervous system applications. While we expect that these types of new products will come to market in the future, it is difficult to estimate when, as the rigors of pharmaceutical regulations affect the timing of product introductions by our pharmaceutical customers that use our drug delivery and dispensing systems.
Consumer Health Care. Sales to the consumer health care market accounted for approximately 22% of the segment’s total net sales in 2020. Many applications for this market are similar to the prescription market; however, these applications are sold over-the-counter without a prescription. Typical consumer health care spray applications include nasal decongestants, nasal salines and cough and cold applications. Typical consumer health care valve applications include nasal saline using our bag-on valve technology. We have developed a multi dose ophthalmic dispensing device suitable for unpreserved formulations. This technology is successfully marketed in Europe, North America and Latin America and is under development for other markets both for over-the-counter and prescription applications. Other products sold to this market include airless pump systems for dermal drug delivery applications. We have recently seen a trend to more child resistant and senior-friendly packaging solutions and have developed products to meet these market needs.
Injectables. Sales to the injectables market accounted for approximately 20% of the segment’s total net sales in 2020. Injectables are elastomeric primary packaging components for injectable drug delivery. Injectable products offered include stoppers for vials and pre-filled syringe components, such as plungers, needle shields, tip caps and components for cartridges. Our recent investment in this business allows us to market coated stoppers which better protect the contents of the vial and the integrity of biologic formulations. Pharmaceutical applications for this market include vaccines, anti-thrombotic, small molecules and biologics.
3/ATR
2020 Form 10-K

Table of Contents
Active Packaging. Active packaging is a technology Aptar acquired in 2018. Sales of active packaging products accounted for approximately 12% of the segment’s total net sales in 2020. Through proprietary material science expertise, we deliver active packaging solutions such as desiccant material to enhance the shelf life and effectiveness of diagnostic and solid dose products. Additionally, the technology is used to absorb moisture and oxygen as well as emit properties such as chlorine dioxide.
BEAUTY + HOME
The Beauty + Home segment is our second largest segment in terms of profitability, accounting for 21% of our Adjusted EBITDA excluding non-allocated corporate costs, and is our largest segment in terms of net sales and total assets representing 44% and 40% of our Net Sales and Total Assets, respectively, in 2020. The Beauty + Home segment primarily sells pumps and decorative components to the beauty market and pumps, closures, aerosol valves, accessories and sealing solutions to the personal care and home care markets. We believe we are a leading supplier for the majority of the products we sell primarily to the beauty and personal care markets.
Beauty. Sales to the beauty market accounted for approximately 46% of the segment’s total net sales in 2020. The beauty market requires a broad range of spray and lotion pumps, closures, elastomeric flow-control components and sampling dispensing systems to meet functional as well as aesthetic requirements. A considerable amount of research and coordination with our customers is required to qualify a pump for use with their products. Within the market, we expect the use of pumps to continue to increase, particularly in the cosmetics and sampling sectors. In the cosmetic sector, packaging for certain products such as natural and organic cosmetics and anti-aging lotions continue to provide us with growth opportunities. We are a leading provider of packaging solutions for prestige and mass market fragrance products. Our cosmetic lotion pumps, airless dispensing systems, lotion sampling devices and decorative capabilities along with our focus on color cosmetics including lip stick and lip gloss products will also provide growth opportunities. We see significant opportunities for growth in the sale of our products for cosmetic skin care and color cosmetic applications in Asia.
Personal Care. Sales to the personal care market accounted for approximately 46% of the segment’s total net sales in 2020 and primarily included sales of lotion pumps, closures, fine mist spray pumps, continuous spray aerosol valves, and elastomeric flow-control components. Personal care lotion pump applications include hand sanitizers, soaps, cleaners, and skin moisturizers. Personal care closures applications include hand sanitizers, shampoos and conditioners. Typical spray pump applications include hair care, body care and sun care products. Personal care continuous spray aerosol valve applications include hair care products, deodorants, shaving creams and sun care products. Our research and development teams continue to design unique accessories that increase the value of our continuous spray aerosol valve offerings.
Home Care. Sales to the home care market accounted for approximately 8% of the segment’s total net sales in 2020 and primarily included sales of continuous or metered dose spray aerosol valves, closures and to a lesser degree spray and lotion pumps. Applications for continuous spray valves include disinfectants, spray paints, insecticides and automotive products. Metered dose valves are used for air fresheners. Closure applications include liquid detergents, automotive products and household cleansers. Spray and lotion pump applications primarily include household, insect repellent and industrial cleaners.
FOOD + BEVERAGE
The Food + Beverage segment is our smallest segment in terms of profitability, net sales and total assets, representing 11%, 14% and 14%, respectively, of our Adjusted EBITDA excluding non-allocated corporate costs, Net Sales and Total Assets in 2020. We primarily sell dispensing closures and, to a lesser degree, non-dispensing closures, elastomeric flow control components, spray pumps and aerosol valves.
Sales of dispensing closures have grown as consumers worldwide have demonstrated a preference for a package utilizing the convenience of a dispensing closure. At the same time, consumer marketers are trying to differentiate their products by incorporating performance enhancing features such as bonded aluminum liners to plastic, flow-control and no-drip dispensing, inverted packaging and directional flow to make packages simpler to use, cleaner and more appealing to consumers. We also have an increasing number of product solutions that address the increased use of flexible packaging formats.
Food. Sales to the food market accounted for approximately 75% of the segment’s total net sales in 2020 and primarily include sales of dispensing closures and elastomeric flow-control components. To a lesser degree we also sell non-dispensing closures, continuous spray aerosol valves and spray pumps to this market. Applications for dispensing closures include sauces, condiments, infant nutrition and other food products. Applications for continuous spray aerosol valves include cooking sprays. Spray pump applications primarily include butter sprays. We also leverage our material science technology to sell and further develop packaging solutions to the food service market to enhance the shelf life of those products.
Beverage. Sales to the beverage market accounted for approximately 25% of the segment’s total net sales in 2020 and primarily include sales of dispensing closures and elastomeric flow-control components. Sales of dispensing closures to the beverage market have increased significantly over the last several years as we continue to see an increase of interest from marketers using dispensing closures for their products. Examples of beverage products currently utilizing dispensing closures include bottled water, sport and energy drinks, juices and concentrated water flavorings.
4/ATR
2020 Form 10-K

Table of Contents
GENERAL BUSINESS INFORMATION
RESEARCH AND DEVELOPMENT
Our commitment to innovation, one of our competitive strengths, has resulted in an emphasis on research and development directed toward developing affordable, new, sustainable and innovative packaging, drug delivery solutions and connected devices and adapting existing products for new markets or customer requirements. In certain cases, our customers share in the research and development expenses of customer initiated projects. Occasionally, we acquire or license from third parties technologies or products that are in various stages of development.
PATENTS AND TRADEMARKS
We customarily seek patent and trademark protection for our products and brands. We own and currently have numerous applications pending for patents and trademarks in many regions of the world. In addition, certain of our products are produced under patent licenses granted by third parties. We believe that we possess certain technical capabilities and know-how that make our products difficult for a competitor to duplicate. While valuable to our overall product portfolio, sales of any one individually patented product are not considered material to any specific segment or to our consolidated results.
TECHNOLOGY
We have technical expertise regarding injection molding, robotics, clean-room facilities and high-speed assembly. We also have expertise regarding the formulation and finishing of elastomer and silicone components. In addition, we offer a variety of sterilization options for elastomeric components and active packaging technology based on proprietary material science expertise. Pumps and aerosol valves require the assembly of several different plastic, metal and rubber components using high-speed equipment. When molding dispensing closures, or plastic components to be used in pump or aerosol valve products, we use advanced plastic injection molding technology, including large cavitation plastic injection molds. We are able to mold within tolerances as small as one one-thousandth of an inch and we assemble products in a high-speed, cost-effective manner. We also provide analytical and connected device expertise within our pharma service technology businesses.
MANUFACTURING AND SOURCING
The majority of our worldwide production is located outside of the United States. Our philosophy is to produce as much as possible in the region where it will be sold. In order to augment capacity and to maximize internal capacity utilization (particularly for plastic injection molding), we use subcontractors to supply certain plastic, metal and rubber components. Certain suppliers of these components have unique technical abilities that make us dependent on them, particularly for aerosol valve and pump production. The principal raw materials used in our production are plastic resins, silicone, rubber and certain metal products. We believe an adequate supply of such raw materials is available from existing and alternative sources. We attempt to offset cost increases through improving productivity and developing new, higher margin solutions and increasing selling prices, as allowed by market conditions or contractual commitments. We source certain materials, especially some resins and rubber components for our pharmaceutical segment, from a single source. Significant delays in receiving these components or discontinuance of an approved raw material would require us to seek alternative sources, which could result in higher costs as well as impact our ability to supply products in the short-term. While there have been some supply chain disruptions due to confinements through the pandemic, we have not been materially impacted by such disruptions.
CUSTOMERS
We have approximately 6,000 customers with no single customer or group of affiliated customers accounting for greater than 5% of 2020 Net Sales. From time to time our customer base experiences normal consolidation events and this trend is expected to continue. A concentration of customers presents opportunities for increasing sales due to the breadth of our product line, our international presence and our long-term relationships with certain customers. However, consolidation of our customers could lead to pricing pressures, concentration of credit risk and fewer opportunities to introduce new products to the market.
INTERNATIONAL BUSINESS
We are geographically diverse with manufacturing and sales operations in Asia, Europe, Latin America (including Mexico) and North America. Europe is our largest region in terms of sales, where sales (including exports) for the years ended December 31, 2020 and 2019 were approximately 55% and 57%, respectively, of our consolidated sales. Asia and Latin America when aggregated represented approximately 12% and 14% of our consolidated sales for the years ended December 31, 2020 and 2019, respectively. Export sales from the United States were $179.0 million and $170.0 million in 2020 and 2019, respectively. We are a net exporter of goods from Europe and a net importer of goods to the North American, Asian and Latin American regions.
5/ATR
2020 Form 10-K

Table of Contents
FOREIGN CURRENCY
Because of our international presence, movements in exchange rates have a significant impact on the translation of the financial statements of our foreign subsidiaries. Our primary foreign exchange exposure is to the euro, but we have foreign exchange exposure to the Chinese yuan, Brazilian real, Mexican peso, Swiss franc and other Asian, European and South American currencies. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial statements. Conversely, a weakening U.S. dollar has an additive effect. We manage our exposures to foreign exchange principally with forward exchange contracts to economically hedge recorded transactions and firm purchase and sales commitments denominated in foreign currencies.
During the quarter ended June 30, 2018, we concluded that Argentina has become a highly inflationary economy primarily based on published estimates, which indicate that Argentina's three-year cumulative inflation rate has exceeded 100%. Beginning July 1, 2018, we applied highly inflationary accounting for our Argentinian subsidiary. We have changed the functional currency from the Argentinian peso to the U.S. dollar.
EMPLOYEE AND LABOR RELATIONS
Human Capital. Our key human capital management objectives are to attract, retain and develop the highest quality talent. To support these objectives, our human resources programs are designed to develop talent to prepare them for critical roles and leadership positions for the future; reward and support employees through competitive pay, benefit, and incentive programs; enhance our culture through efforts aimed at making the workplace more engaging and inclusive; acquire talent and facilitate internal talent mobility to create a high-performing, diverse workforce; and evolve and invest in technology, tools, and resources to enable employees at work.
As of December 31, 2020, AptarGroup has approximately 13,000 full-time employees. Of the full-time employees, approximately 7,900 are located in Europe, 2,600 are located in Asia and South America and the remaining 2,500 are located in North America. The majority of our European and Latin American employees are covered by collective bargaining arrangements made at either the local or national level in their respective countries and approximately 60 of the North American employees are covered by a collective bargaining agreement. The total labor force covered by a collective bargaining agreement represents 57% of the total employee population. Termination of employees at certain of our international operations could be costly due to local regulations regarding severance benefits. There were no material work stoppages in 2020 and management considers our employee relations to be satisfactory.
Employee Engagement. At AptarGroup, we conduct annual leadership for growth surveys. We have focused on organizational development based on our leadership principles, core values and strategic priorities. Our goal is to ensure that Aptar is well positioned for long-term growth and that we continue to be a high-performing, values-based, customer-focused company, with active commitments to innovation and sustainability.
Employee Development & Leadership Succession. Developing our employees to reach their full potential is an integral part of our Core Values. We have a strong foundation of learning and development systems and leadership programs at our Corporate University. Our leadership programs are targeted at all levels of the organization, from early career to senior leadership globally. Our program offerings also include many specialized programs such as change management, manufacturing and operational leadership, technical skills and others. Aptar also has developed and deployed an integrated talent management system that includes annual talent reviews, three tiered succession planning, and individual development planning. Promotions from within provide career growth opportunities for our employees.
Diversity & Inclusion. At AptarGroup, our goal is to promote a diverse and inclusive culture. Approximately 40% of the Board of Directors is comprised of women and 100% of Board Committee chairs are women. During 2020, we appointed a Diversity & Inclusion Global Leader and trained over 75% of senior leadership in Diversity & Inclusion (D&I) content. Women comprise 37% of the global employee population and 18% at senior leadership levels. Aptar launched a global Women's Employee Resource Group with a focus on increasing women in leadership. Aptar is included in the SPDR SSGA Gender Diversity Index ETF (SHE) which invests in companies that rank among the highest in gender diversity within senior leadership. Aptar is also a participant in the Catalyst CEO Champions for Change and the Gender and Diversity KPI Alliance.
Employee Well-being & Safety. Employee safety and well-being is a primary focus of Aptar and was of particular interest during fiscal year 2020 in light of the COVID-19 pandemic. In response to the pandemic, we have taken a variety of measures to ensure the availability and functioning of our critical infrastructure, to promote the safety and security of our employees, and to support the communities in which we operate. These measures include requiring remote working arrangements for employees where practicable and implementing new safety protocols. We are following public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions, the promotion of social distancing, and the adoption of work-from-home arrangements. Additionally, we expanded employee assistance and mindfulness programs globally to help employees and their families manage anxiety, stress, and overall well-being.


6/ATR
2020 Form 10-K

Table of Contents
COMPETITION
All of the markets in which we operate are highly competitive and we continue to experience price competition in all product lines and markets. Competitors include privately and publicly held entities that range from regional to international companies. We expect the market for our products to remain competitive, as consolidation among our competitors is increasing in the current economic climate. We believe our competitive advantages are consistent high levels of innovation, quality and service, geographic diversity, financial strength and stability and breadth of products and services. Our manufacturing strength lies in the ability to mold complex plastic components and formulate and finish elastomer and silicone components in a cost-effective manner and to assemble products at high speeds. Our business is somewhat capital intensive and it is becoming more important to our customers that we have global manufacturing capabilities. Both of these serve as barriers to entry for new competitors wanting to enter our business. Furthermore, within our Pharma business, increasing regulatory hurdles present a barrier for new competitors to enter the market.
While we have experienced some competition in Europe, Latin America and the United States from low cost Asian suppliers, particularly in the beauty and personal care market, this has not been significant. Although using low cost Asian suppliers may have a cost advantage, some customers prefer local suppliers citing better quality, better customer service and shorter lead times. We have also recently reduced our carbon footprint due to shorter supply chain networks being utilized, which we see as a competitive advantage.
ENVIRONMENT
Our manufacturing operations primarily involve plastic injection molding, automated assembly processes, elastomer and silicone formulation and finishing and, to a limited degree, metal anodization and vacuum metallization of plastic components. Historically, the environmental impact of these processes has been minimal, and we believe we meet current environmental standards in all material respects. To date, our manufacturing operations have not been significantly affected by environmental laws and regulations relating to the environment.
Recently, we formalized our science-based targets setting an emissions reduction goal consistent with requirements to keep global warming well-below 2° Celsius by year 2030. This science-based approach incorporates our own operations and operations within the value chain. In addition, we annually undergo data assurance as part of our sustainability reporting. This assurance process allows for data on consumption of electricity, fuel oil, and natural gas, and renewable energy purchases to be verified for accuracy and completeness by an external organization. Globally this process is certified to the ISO 14064 standard for energy and greenhouse gas emission reporting.
Aptar was recognized for its actions to cut emissions, mitigate climate risks and further the low-carbon economy, based on the data reported by the Company through global environmental non-profit CDP's 2020 climate change questionnaire. Of more than 5,800 companies that were scored through the platform, Aptar is among the 273 companies securing a place on its prestigious 'A List' for tackling climate change. Through significant demonstrable action on climate change, Aptar is leading on corporate environmental ambition, action, and transparency worldwide.
There continues to be increased interest and awareness from consumers, and from our customers, in environmentally sustainable products, especially through the sourcing of sustainable materials. We are focused on reducing our environmental impacts through product life cycle assessments, sustainable material trials, operational eco-efficiency initiatives and renewable energy sourcing. We have teams dedicated to designing for sustainability by providing products that improve recyclability and use less material. Aptar has launched products and components in North America, Europe and Asia made with post-consumer recycled resins (PCR) and continues to explore additional opportunities for alternative resins and recyclable products.
We are actively collaborating with our customers on reliable products by supporting our customers’ participation in the circular e-commerce platform called “Loop,” in addition to being an investor in Loop ourselves. We also invested in and partnered with PureCycle, to prepare for the introduction of Ultra-Pure Recycled Polypropylene (UPRP) into dispensing applications.
Connecting with other companies through organizations like Ellen MacArthur Foundation’s New Plastics Economy and the World Business Council for Sustainable Development (WBCSD) provides an invaluable opportunity to share best practices and work on larger projects with aligned objectives towards a more circular economy.
Future regulations on environmental matters regarding recycling or material inputs could impact our business.
7/ATR
2020 Form 10-K

Table of Contents
GOVERNMENT REGULATION
Certain of our products are directly or indirectly affected by government regulation. The European Union has adopted a circular economy package. The package maps out a series of actions planned over several years. Some actions have resulted in regulations aimed to reduce marine litter, increase plastic recycling rates, prohibit single-use plastic packaging and introduce new taxes in relation to the end-of-life management of packaging. In parts of the United States, regulations require food and beverage companies to tether plastic caps to ensure the caps stay with the package, thus improving the likelihood the caps will enter the recycling stream. The potential exists for these types of regulations to expand worldwide. We have established an innovation team that focuses on designing for and converting into more sustainable options like post-consumer recycled resin and Food and Drug Administration approved resin alternatives. We are designing for sustainability by providing products that improve recyclability and use less material, and we offer multiple tethered options. We are also partnering with global and regional thought leaders to drive a more circular economy.
The Kigali amendment to the Montreal Protocol plans to phase down hydrofluorocarbon (HFC) propellants from baseline to 15% in order to reduce greenhouse gas emission. This type of propellant is used for pressurized metered-dose inhalers (pMDI). The phase down plan has an exemption for pharmaceutical applications of pMDIs; however, customers are looking for alternative propellants to reduce greenhouse gas emissions. We are working with the suppliers of these alternative propellants and our customers to develop new solutions.
Future government regulations could include healthcare cost containment policies. For example, reviews by various governments to determine the number of drugs, or prices thereof, that will be paid by their insurance systems could affect future sales of our pharmaceutical customers’ products and thus adversely impact our sales to these customers. Such regulation could adversely affect prices of and demand for our pharmaceutical products. We believe that the focus on the cost effectiveness of the use of medications as compared to surgery and hospitalization provides us with an opportunity to expand sales to the pharmaceutical market.
8/ATR
2020 Form 10-K

Table of Contents
INFORMATION ABOUT OUR EXECUTIVE OFFICERS
Our executive officers as of February 19, 2021 are as follows:
NameAgePosition with the Company
Stephan Tanda55President and Chief Executive Officer
Mr. Tanda has been President and Chief Executive Officer since February 2017. Prior to this, Mr. Tanda was an Executive Managing Board Director at Royal DSM NV, a leading global supplier of ingredients and material solutions for the food, dietary supplement, personal care, medical device, automotive, paint, electronic and bio-material markets, from March 2007 to January 2017.
Robert Kuhn58Executive Vice President and Chief Financial Officer
Mr. Kuhn has been Executive Vice President and Chief Financial Officer since September 2008. Mr. Kuhn served as Secretary from June 2011 to January 2021.
Marc Prieur55President, Aptar Beauty + Home
Mr. Prieur has been President of Aptar Beauty + Home since December 2019. Prior to this, Mr. Prieur was President of Aptar Food + Beverage from September 2018 to November 2019, VP of Aptar Operational Excellence from June 2017 to August 2018, President EMEA Sales & Operations – Consumer Health Care from June 2013 to June 2017 and President of our Pharma business in Asia from June 2008 to June 2013.
Hedi Tlili46President, Aptar Food + Beverage
Mr. Tlili has been President of Aptar Food + Beverage since December 2019. Prior to this, Mr. Tlili was President of Aptar EMEA Beauty + Home from June 2018 to November 2019 and President of Aptar EMEA Food + Beverage from May 2016 to May 2018. Prior to joining Aptar, Mr. Tlili held leadership positions at our packaging solutions peers Albéa and Sonoco. He was a Cluster Deputy Manager in Albéa Group from September 2014 to March 2016, Country General Manager in Sonoco from April 2013 to June 2014 and European Sales and Marketing Director from September 2011 to March 2013 in Sonoco.
Gael Touya51President, Aptar Pharma
Mr. Touya has been President of Aptar Pharma since September 2018. Prior to this, Mr. Touya was President of Aptar Food + Beverage from 2016 to August 2018, President of Aptar Food + Beverage Europe from 2012 to 2015 and Business Development Vice President Skin Care and Color Cosmetics from 2010 to 2011.
Xiangwei Gong51President, Aptar Asia
Ms. Gong has been President of Aptar Asia since October 2018. Prior to this, Ms. Gong held various leadership positions at Royal DSM for over 22 years. She was President of DSM Hydrocolloids from 2014 to 2018, President Asia of DSM Food Specialties from 2011 to 2014, Vice President of Channel Marketing from 2008 to 2011 and Vice President of Personal Care in DSM North America from 2005 to 2008.
Shiela Vinczeller57Chief Human Resources Officer
Ms. Vinczeller has been Chief Human Resources Officer since November 2018. Prior to this, Ms. Vinczeller spent 12 years in Human Resources leadership roles at International Paper, one of the world’s leading producers of fiber-based packaging, pulp and paper.
Kimberly Y. Chainey45Executive Vice President, General Counsel and Secretary
Ms. Chainey has been Executive Vice President and global General Counsel since July 2020. Ms. Chainey has been Secretary since January 2021. Prior to this, Ms. Chainey was Vice President and General Counsel at Panasonic Avionics Corporation, a global manufacturer of in-flight entertainment and communications solutions, from January 2019 to July 2020 and Associate General Counsel at Avis Budget Group, a global provider of mobility solutions, from November 2014 to December 2018.
There were no arrangements or understandings between any of the executive officers and any other person(s) pursuant to which such officers were elected.
9/ATR
2020 Form 10-K

Table of Contents
ITEM 1A. RISK FACTORS
Set forth below and elsewhere in this report and in other documents we file with the Securities and Exchange Commission are risks and uncertainties that could cause our actual results or other events to materially differ from the results or events contemplated by the forward-looking statements contained in this report and in other documents we file with the Securities and Exchange Commission. Additional risks and uncertainties not presently known to us, or that we currently deem immaterial, may also impair our business operations. You should carefully consider the following factors in addition to other information contained in this Form 10-K before purchasing any shares of our common stock.
Risks Related to Our Operations and Industry
The COVID-19 pandemic continues to adversely affect our business. Additional factors could exacerbate such negative consequences and/or create materially adverse effects. The COVID-19 pandemic adversely affected our sales of products to our travel and retail beauty business and on-the-go beverage customers during the year ended December 31, 2020 and that adverse impact will continue into 2021 as the pandemic continues globally. Beginning in the first quarter of 2020, economic and health conditions in the United States and across most of the globe have changed rapidly. Customer demand across all segments, particularly our Beauty + Home and Food + Beverage segments, may decrease further from historical levels depending on the duration and severity of the COVID-19 pandemic and the extent of further resurgences, the availability, adoption and effectiveness of a vaccine, the length of time it takes for normal economic and operating conditions to resume, additional governmental actions that may be taken and/or extensions of time for restrictions that have been imposed to date, and numerous other uncertainties. Such events may result in business and manufacturing disruption, inventory shortages due to disruptions to our supply chain and distribution channels, delivery delays, increased risk associated with customer payments and reduced sales and operations, any of which could materially affect our stock price, business prospects, financial condition, results of operations and liquidity.
The ability of our employees to work may be significantly impacted by COVID-19. The majority of our office and management personnel are working remotely and the majority of our facilities remained operational during 2020 as each of our segments produce dispensing systems that have been determined to be essential products by various government agencies around the world. The health and safety of our workforce is of primary concern and we may need to enact further precautionary measures to help minimize the risk of our employees being exposed to the virus and overall organization fatigue. Further, our management team is focused on mitigating the adverse effects of the COVID-19 pandemic, which has required and will continue to require a large investment of time and resources across the entire company, thereby diverting their attention from other priorities that existed prior to the outbreak of the pandemic. Incremental operating costs related to heightened cleaning and sanitizing procedures at our factories, personal protective equipment for our employees and temporary labor costs necessary to address absenteeism, among others, will be necessary as the pandemic continues in the near-term. If these conditions worsen, or last for an extended period of time, our ability to manage our business may be impaired, and operational risks, cybersecurity risks and other risks facing us even prior to the pandemic may be elevated.
If there is deterioration in economic conditions in a particular region or market, our business and operating results could be materially adversely impacted. Due to our strong balance sheet, diverse product offerings, various end-markets served, and our broad geographic presence, we believe we are well positioned to withstand temporary slowness in any one particular region or market. However, economic uncertainties affect businesses such as ours in a number of ways, making it difficult to accurately forecast and plan our future business activities. A tightening of credit in financial markets or other factors may lead consumers and businesses to postpone spending, which may cause our customers to cancel, decrease or delay their existing and future orders with us. In addition, financial difficulties experienced by our suppliers, customers or distributors could result in product delays, increased accounts receivable defaults, inventory or supply challenges and pricing pressures. An interruption in supply may also impact our ability to meet customer demands. Consumer demand for our customers’ products and shifting consumer preferences are unpredictable and could have a negative impact on our customers and our customers’ demand for our products.
We face strong global competition and our market share could decline. All of the markets in which we operate are highly competitive and we continue to experience competition in all product lines and segments. Competitors, including privately and publicly held entities that range from regional to international companies, are becoming increasingly credible in the core markets in which we do business. We expect the market for our products to remain competitive, as consolidation among our competitors is increasing in the current economic climate and exclusivity arrangements with customers may drive the creation of new competitors in the market.
Customers and consumers are increasingly requesting solutions that can be refilled and reused as the market moves toward more sustainable, environmentally-friendly products. A competitor's design innovation or ability to provide more sustainable products could have an adverse impact on our business. If we are unable to compete successfully, our market share may decline, which could materially adversely affect our results of operations and financial condition.
10/ATR
2020 Form 10-K

Table of Contents
Geopolitical conditions, including trade disputes and direct or indirect acts of war or terrorism, could have a material adverse effect on our operations and financial results. Our operations could be disrupted by geopolitical conditions such as Brexit, trade disputes, international boycotts and sanctions, political and social instability, acts of war, terrorist activity or other similar events. Such events could make it difficult, impossible or more expensive to manufacture or deliver products to our customers, receive production materials from our suppliers, or perform critical functions, all of which could adversely affect our business globally or in certain regions. In addition, our customers may export their finished products using our dispensing devices that were sold in other regions and an adverse geopolitical event may impact the sales of our customers’ products and thus indirectly negatively impact the demand for our dispensing solutions. Although, our business is well-diversified across nine end markets and many geographies as we produce in seventeen countries and we believe our diverse business model, coupled with our diverse and global customer base, allow some protection from dependency on any one geographic region, country or even trade route, our diversification efforts may not be successful in insulating our operations from disruptive geopolitical conditions and we do face some risk related to specific trade policies.
Consolidation of our customer base could impact our business. We believe mergers and acquisitions within our customer base create opportunities for increasing sales due to the breadth of our product line, our international presence and our long-term relationships with certain customers. However, consolidation of our customers could lead to pricing pressures, concentration of credit risk and fewer opportunities to introduce new products to the market.
The success or failure of our customers’ products, particularly in the pharmaceutical market, may materially affect our operating results and financial condition. In the pharmaceutical market, the proprietary nature of our customers’ products and the success or failure of their products in the market using our dispensing systems may have a material impact on our operating results and financial condition. We may potentially work for years on modifying our dispensing device to work in conjunction with a customer’s drug formulation. If the customer’s pharmaceutical product is not approved by regulatory bodies or it is not successful on the market, the associated costs may not be recovered.
Higher raw material costs and other inputs and an inability to increase our selling prices may materially adversely affect our operating results and financial condition. The cost of raw materials and other inputs (particularly plastic resin, rubber, metal, anodization costs and transportation and energy costs) are volatile and susceptible to rapid and substantial changes due to factors beyond our control, such as changing economic conditions, currency fluctuations, weather conditions, political unrest and instability in energy-producing nations, and supply and demand pressures. Raw material costs may increase in the coming years due to market fluctuation and the use of post-consumer resin for our sustainable product offerings and, although we have generally been able to increase selling prices to cover increased costs, future market conditions may prevent us from passing these increased costs on to our customers through timely price increases. In addition, we may not be able to improve productivity or realize savings from our cost reduction programs sufficiently enough to offset the impact of increased raw material costs. As a result, higher raw material costs could result in declining margins and operating results.
In difficult market conditions, our fixed costs structure combined with potentially lower revenues may negatively impact our results. Our business is characterized by relatively high fixed costs and, notwithstanding our utilization of third-party manufacturing capacity, most of our production requirements are met by our own manufacturing facilities. In difficult environments, we are generally faced with a decline in the utilization rates of our manufacturing facilities due to decreases in product demand. During such periods, our plants may not operate at full capacity and the costs associated with this excess capacity are charged directly to cost of sales. Difficult market conditions in the future may adversely affect our utilization rates and consequently our future gross margins, and this, in turn, could have a material negative impact on our business, financial condition and results of operations.
If our unionized employees were to engage in a strike or other work stoppage, our business, operating results and financial position could be materially adversely affected. The majority of our European and Latin American employees are covered by collective bargaining arrangements made either at the local or national level in their respective countries and approximately 60 of our North American employees are covered by a collective bargaining agreement. Although we believe that our relations with our employees are satisfactory, no assurance can be given that this will continue. If disputes with our unions arise, or if our unionized workers engage in a strike or other work stoppage, we could incur higher labor costs or experience a significant disruption of operations, which could have a material adverse effect on our business, operating results and financial position.
Single sourced materials and manufacturing sites could adversely impact our ability to deliver product. We source certain materials, especially some resins and rubber components for our pharmaceutical segment, from a single source. Any disruption in the supply of these materials could adversely impact our ability to deliver product to our customers. Similarly, we have certain components and products that are manufactured at a single location or from a single machine or mold. Any disruption to the manufacturing process could also adversely impact our ability to deliver product to our customers.
If we were to incur a significant product liability claim above our current insurance coverage, our business, operating results and financial condition could be materially adversely affected. The failure of our devices to operate as intended may result in a product liability claim against us. We believe we maintain adequate levels of product liability insurance coverage. A product liability claim in excess of our insurance coverage or not covered by existing insurance may materially adversely affect our business, operating results and financial condition.
11/ATR
2020 Form 10-K

Table of Contents
Increased cybersecurity threats could pose a risk to our operations. Increased global information security threats and more sophisticated, targeted computer crime pose a risk to the confidentiality, availability and integrity of our data, operations and infrastructure, as well as the data of our customers. We continue to assess potential threats and make investments seeking to reduce the risk of these threats by employing a number of security measures, including employee training, comprehensive monitoring of our networks and systems, ensuring strong data protection standards including authentication mechanisms are in place, and safeguarding our critical information assets. We also periodically test our systems for vulnerabilities and regularly rely on third parties to conduct such tests. To date, we have seen no material impact on our business or operations from these threats; however, we cannot guarantee that our security efforts will prevent unauthorized access or loss of functionality to our or our third-party providers’ systems. Even with these mitigations, our information systems remain potentially vulnerable to sophisticated cybersecurity threats, particularly as more business activities have shifted online due to the COVID-19 pandemic. Depending on their nature and scope, such threats could potentially lead to the compromise of confidential information, improper use of our systems and networks, manipulation and destruction of data, production downtimes and operational disruptions, which in turn could adversely affect our reputation, competitiveness and results of operations.
If our integration of acquisitions are unsuccessful, our financial performance may suffer. We continue to pursue growth through acquisitions, including the recent Fusion, Noble, Nanopharm and Gateway acquisitions. If our integration efforts, including unlocking synergies, are unsuccessful we may not realize the full potential of the acquisitions and as a result our financial performance may suffer.
We are currently implementing a business transformation plan, with the main objective to return our Beauty + Home segment to historical growth and profit margins. Certain elements of this transformation plan can be disruptive to our business and our employees if we do not manage the change properly. Furthermore, ongoing changes in material indices, macro-economic trends and other factors have resulted in negative headwinds, and may continue to negatively impact our transformation plan. In addition, the current COVID-19 pandemic has adversely impacted, and may continue to adversely impact, the timing and extent of declines in customer orders and delays in certain footprint optimization plans. As a result of the foregoing, the transformation plan is taking longer to complete than currently expected, may be more costly to complete than currently expected and may not be successful in returning Beauty + Home to historical growth and profit margins. Any such effects could materially adversely impact our business.
Risks Related to Financial, Legal and Regulatory Matters
We have foreign currency translation and transaction risks that may materially adversely affect our operating results. A majority of our operations are located outside of the United States. Because of this, movements in exchange rates may have an impact on the translation of the financial statements of our foreign entities. Our primary foreign exchange exposure is to the euro, but we have foreign exchange exposure to the Chinese yuan, Brazilian real, Mexican peso, Swiss franc, and other Asian, European and South American currencies. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial statements. Conversely, a weakening U.S. dollar has an additive translation effect. In some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. We manage our exposures to foreign exchange principally with forward exchange contracts to economically hedge certain transactions and firm purchase and sales commitments denominated in foreign currencies. The volatility of currency exchange rates may materially affect our operating results.
We have approximately $898.5 million in recorded goodwill at December 31, 2020, and changes in future business conditions could cause this asset to become impaired, requiring write-downs that would reduce our operating income. We evaluate the recoverability of goodwill amounts annually, or more frequently when evidence of potential impairment exists. The impairment test is based on several factors requiring judgment. A decrease in expected reporting unit cash flows or changes in market conditions, including as a result of the COVID-19 pandemic, may indicate potential impairment of recorded goodwill and, as a result, our operating results could be materially adversely affected. See “Critical Accounting Estimates” in Part II, Item 7 for additional information.
Government regulation on environmental matters regarding recycling or environmental sustainability policies could impact our business. Future government regulations mandating the use or limitations of certain materials could impact our manufacturing processes or the technologies we use forcing faster development and adoption of alternative materials or assets used in the production of our products.
Future government regulations of healthcare cost containment policies may impact our pharmaceutical sales. Review by governments of the number of drugs and prices thereof that will be paid by their insurance systems could affect future sales to the pharmaceutical industry and thereby adversely affect prices of and demand for our pharmaceutical products.
12/ATR
2020 Form 10-K

Table of Contents
We may be adversely affected by the transition away from the London Interbank Offered Rate (“LIBOR”) or other Interbank Rates (IBORs) to Risk Free Rates for our variable rate loans, derivative contracts and other financial assets and liabilities. We have loans, derivative contracts and other financial instruments which are directly or indirectly dependent on LIBOR to establish their interest rate and/or value. The U.K. Financial Conduct Authority, which is the LIBOR administrator's regulator, announced in 2017 that it would no longer compel banks to submit rates for the calculation of LIBOR after 2021. However, for U.S. dollar LIBOR, it now appears that the relevant date may be deferred to June 30, 2023 for the most common tenors (overnight and one, three, six and 12 months). As to those tenors, the LIBOR administrator has published a consultation regarding its intention to cease publication of U.S. dollar LIBOR as of June 30, 2023 (instead of December 31, 2021, as previously expected), apparently based on continued rate submissions from banks. An extension to 2023 would mean that many legacy U.S. dollar LIBOR contracts would terminate before related LIBOR rates cease to be published. Although the foregoing may provide some sense of timing, there is no assurance that LIBOR, of any particular currency and tenor, will continue to be published until any particular date, and it appears highly likely that LIBOR will be discontinued or modified after December 31, 2021 or June 30, 2023, depending on the currency and tenor.
The transition from LIBOR may cause us to incur increased costs and additional risk. Uncertainty as to the nature of alternative reference rates and as to potential changes in or other reforms to LIBOR may adversely affect LIBOR rates and the value of LIBOR-based loans. If LIBOR rates are no longer available, any successor or replacement interest rates may perform differently, which may affect our net interest expense, change our market risk profile and require changes to our risk, pricing and hedging strategies. We will continue our impact assessment and monitor regulatory developments during the transition period.
General Risk Factors
Ownership by Certain Significant Stockholders. Currently, Aptar has four institutional stockholders who each own between 6% and 11% of our outstanding common stock. None of these stockholders have direct representation on our Board of Directors. If one of these stockholders decides to sell significant volumes of our stock, this could put downward pressure on the price of the stock.
We could be subject to changes in tax rates, the adoption of new tax legislation or rules or exposure to additional tax liabilities. Due to economic and political conditions, tax rates in the various jurisdictions in which we operate may be subject to change. Our effective tax rate could be affected by changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, the introduction of new taxes, or changes in tax laws or their interpretation. While no formal proposals exist, currently discussed tax rate changes in the U.S. would have a materially adverse impact on our reported tax expense and operating results.
We are also subject to examination of our returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and governmental bodies. We regularly assess the likelihood of an adverse outcome resulting from these examinations to determine the adequacy of its provision for taxes. There can be no assurance as to the outcome of these examinations. If our effective tax rates were to increase in jurisdictions where we have significant operations, or if the ultimate determination of taxes owed is for an amount in excess of amounts previously accrued, our financial condition and operating results could be materially adversely affected.
ITEM 1B. UNRESOLVED STAFF COMMENTS
We have no unresolved comments from the SEC.
13/ATR
2020 Form 10-K

Table of Contents
ITEM 2. PROPERTIES
We lease or own our principal offices and manufacturing facilities. None of the owned principal properties is subject to a lien or other encumbrance material to our operations. We believe that existing operating leases will be renegotiated as they expire, will be acquired through purchase options or that suitable alternative properties will be leased on acceptable terms. We consider the condition and extent of utilization of our manufacturing facilities and other properties to be generally good, and the capacity of our plants to be adequate for the needs of our business. We manufacture products in 49 locations, with 19 of those facilities serving two segments and 5 serving all three of our segments. The locations of our manufacturing facilities, by geographic region/country, are set forth below:
Geographic Region/CountryNumber of Manufacturing FacilitiesPharma Manufacturing FacilitiesBeauty + Home Manufacturing FacilitiesFood + Beverage Manufacturing Facilities
France10661
Germany6351
Rest of Europe9285
North America11676
Latin America8183
China2222
Other Asia3121
Total49213819
Our head corporate office is located in Crystal Lake, Illinois. We also have sales personnel, service facilities, and corporate offices in locations in addition to those listed above.
ITEM 3. LEGAL PROCEEDINGS
In the normal course of business, we are subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position or results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur that could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows. Please refer to Note 13 - Commitments and Contingencies in Item 8 – Consolidated Financial Statements and Supplementary Data for further discussion of contingencies affecting our business.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
14/ATR
2020 Form 10-K

Table of Contents
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
MARKET FOR REGISTRANT’S COMMON EQUITY
Our Common Stock is traded on the New York Stock Exchange under the symbol “ATR”. As of February 15, 2021, there were approximately 180 holders of record of our Common Stock. A substantially greater number of holders of our Common Stock are “street name” or beneficial holders, whose shares of record are held by banks, brokers, and other financial institutions.
DIVIDENDS
On January 14, 2021, our Board of Directors declared a quarterly cash dividend of $0.36 per share of Common Stock, which was paid on February 17, 2021 to stockholders of record as of January 27, 2021. While we expect to continue to pay a regular quarterly dividend of $0.36 per share in 2021, the timing, declaration, amount and payment of any future cash dividends are at the discretion of the Board of Directors and will depend on our available cash, working capital, financial condition, results of operations, capital requirements, covenants in our credit facility, applicable law and other factors that our Board of Directors considers relevant.
RECENT SALES OF UNREGISTERED SECURITIES
Certain French employees are eligible to participate in the FCP Aptar Savings Plan (the “Plan”). An independent agent purchases shares of Common Stock available under the Plan for cash on the open market and we do not issue shares. We do not receive any proceeds from the purchase of Common Stock under the Plan. The agent under the Plan is Banque Nationale de Paris Paribas Fund Services. No underwriters are used under the Plan. All shares are sold in reliance upon the exemption from registration under the Securities Act of 1933 provided by Regulation S promulgated under that Act. During the quarter ended December 31, 2020, the Plan purchased 1,450 shares of our Common Stock on behalf of the participants at an average price of $118.19 per share, for an aggregate amount of $171 thousand, and sold 7,299 shares of our Common Stock on behalf of the participants at an average price of $123.98 per share, for an aggregate amount of $905 thousand. At December 31, 2020, the Plan owned 85,127 shares of our Common Stock.
ISSUER PURCHASES OF EQUITY SECURITIES
On April 18, 2019, we announced a share repurchase authorization of up to $350 million of Common Stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.
In 2020, we did not repurchase any shares. As of December 31, 2020, there was $278.5 million of authorized share repurchases available to us. Amid the COVID-19 pandemic, we have been focused on preserving our liquidity and therefore temporarily suspended our share repurchase plan in 2020. While we will continue to assess the impact the pandemic is having on our business throughout 2021, we are removing the aforementioned suspension in order to preserve our flexibility to make repurchases from time to time depending on market conditions.
15/ATR
2020 Form 10-K

Table of Contents
SHARE PERFORMANCE
The following graph shows a five year comparison of the cumulative total stockholder return on our Common Stock as compared to the cumulative total return of the Standard & Poor’s 500 Composite Stock Price Index and to an index of peer group companies we selected. The companies included in the peer group are: Albemarle Corporation, Ashland Global Holdings Inc., Berry Global Group, Inc., Catalent, Inc., CCL Industries Inc., Hill-Rom Holdings, Inc., ICU Medical, Inc., Ingredion Inc., International Flavors & Fragrances, Inc., McCormick & Company, Inc., Sealed Air Corporation, Sensient Technologies Corporation, Silgan Holdings, Inc., Sonoco Products Company, Stericycle, Inc., STERIS plc, Teleflex Inc. and West Pharmaceutical Services, Inc.
Comparison of 5 Year Cumulative Stockholder Returns
atr-20201231_g2.jpg
The graph and other information furnished in the section titled “Share Performance” under this Part II, Item 5 of this Form 10-K shall not be deemed to be “soliciting” material or to be “filed” with the Securities and Exchange Commission or subject to Regulation 14A or 14C, or to the liabilities of Section 18 of the Securities Exchange Act of 1934, as amended.
16/ATR
2020 Form 10-K

Table of Contents
ITEM 6. SELECTED FINANCIAL DATA
FIVE YEAR SUMMARY OF SELECTED FINANCIAL DATA
Dollars in millions, except per share data
Years Ended December 31,20202019201820172016
Statement of Income Data:
Net Sales$2,929.3 $2,859.7 $2,764.8 $2,469.3 $2,330.9 
Cost of sales (exclusive of depreciation and amortization shown below)1,842.8 1,818.4 1,813.0 1,603.1 1,496.2 
Selling, research & development and administrative500.2 454.6 430.0 387.4 366.3 
Depreciation and amortization220.3 194.6 171.7 153.1 154.8 
Restructuring initiatives26.5 20.5 63.8 2.2 — 
Operating Income339.5 371.7 286.3 323.5 313.7 
Net Income214.1 242.2 194.8 220.0 205.6 
Net Income Attributable to AptarGroup, Inc.214.0 242.2 194.7 220.0 205.6 
Per Common Share:
Earnings per Share - Basic3.32 3.81 3.12 3.52 3.27 
Earnings per Share - Diluted3.21 3.66 3.00 3.41 3.17 
Cash Dividends Declared1.44 1.42 1.32 1.28 1.22 
Balance Sheet and Other Data:
Cash Flow from Operating Activities$570.2 $514.5 $313.6 $324.7 $325.3 
Capital Expenditures246.0 242.3 211.3 156.6 129.0 
Total Assets3,990.1 3,562.1 3,377.7 3,137.8 2,606.8 
Long-Term Obligations1,055.0 1,085.5 1,126.0 1,191.1 772.7 
Net Debt (1)872.5 953.7 1,028.1 544.7 480.3 
Total Stockholders’ Equity1,850.8 1,572.3 1,422.9 1,312.0 1,174.2 
Interest Bearing Debt to Total Capitalization (2)38.8 %43.2 %47.6 %48.9 %44.6 %
Net Debt to Net Capital (3)32.0 %37.8 %41.9 %29.3 %29.0 %
Percentage of Net Sales:
Cost of sales (exclusive of depreciation and amortization shown below)62.9 %63.6 %65.6 %64.9 %64.2 %
Selling, research & development and administrative17.1 %15.9 %15.6 %15.7 %15.7 %
Operating Income11.6 %13.0 %10.3 %